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RÉSUMÉ 
La chimiothérapie à la doxorubicine est efficace et est largement utilisée pour traiter la leucémie 
lymphoblastique aiguë. Toutefois, son efficacité est entravée par un large spectre de cardiotoxicités 
incluant des changements affectant à la fois la morphologie et la fonction du myocarde. Ces 
changements dépendent principalement de la dose cumulée administrée au patient. Actuellement, 
très peu de techniques sont disponibles pour détecter de telles cardiotoxicités. L'utilisation 
d’images de fibres musculaires (par exemple, à l’aide de l’imagerie des tenseurs de diffusion par 
IRM) ou des techniques d'imagerie 3D (par exemple, ciné DENSE IRM) sont des alternatives 
prometteuses, cependant, leur application en clinique est limitée en raison du temps d'acquisition 
d’images et les erreurs d'estimation qui en résultent. 
En revanche, l'utilisation de l'IRM multi-paramétrique ainsi que le ciné IRM sont des alternatives 
prometteuses, puisque ces techniques sont déjà disponibles au niveau clinique. L’IRM 
multiparamétrique incluant l’imagerie des temps de relaxation T1 et T2 peut être utile dans la 
détection des lésions dans le tissu du myocarde alors que l’imagerie ciné IRM peut être plus 
appropriée pour détecter les changements fonctionnels au sein du myocarde. La combinaison de 
ces deux techniques peut également permettre une caractérisation complète de la fonction du tissu 
myocardique. 
Dans ce projet, l'utilisation des temps de relaxation T1 pré- et post-gadolinium et T2 est d'abord 
évaluée et proposée pour détecter les dommages myocardiques induits par la chimiothérapie à la 
doxorubicine. En second lieu, l'utilisation de patrons 2D de déplacements myocardiques est évaluée 
dans le cadre de la détection des dommages myocardiques et altération fonctionnelle due au 
traitement à la doxorubicine. Enfin, l'utilisation de la modélisation par éléments finis, incluant les 
contraintes et déformations mécaniques est proposée pour évaluer les changements dans les 
propriétés mécaniques au niveau du myocarde, avec l’hypothèse que le traitement à base de 
doxorubicine induit des changements importants à la fois dans le tissu et au niveau de la fonction 
myocardique. 
Dans notre cohorte de survivants de cancer, des changements myocardiques locaux ont été trouvés 
entre le groupe à risque standard et le groupe à risque élevé lorsque le T1 pré-gadolinium fut utilisé. 
Ces changements ont été amplifiés avec l’utilisation d’agent de contraste tel que confirmé par le 
coefficient de partition, ce qui suggère que l’utilisation du T1 post-gadolonium et le coefficient de 
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partition peuvent être des biomarqueurs d'imagerie utiles dans la détection des cardiomyopathies 
induites par la doxorubicine. D’autre part, l'utilisation de T2 a montré que le groupe à risque élevé 
avait un T2 plus élevé comparé au groupe à risque standard et similaire aux valeurs rapportées dans 
la littérature. Toutefois, une plus grande cohorte de survivants de cancer peut être nécessaire pour 
évaluer l'utilisation des temps de relaxation T1 et T2 comme étant des indices éventuels de 
détection des dommages myocardiques dans le contexte de la cardiotoxicité induite par la 
doxorubicine. 
Dans la même cohorte de volontaires qui ont été évalués dans cette étude, les patrons de 
déplacement myocardiques étaient significativement plus faibles chez les survivants du cancer 
comparativement aux volontaires sains, bien que la signature des courbes de déplacement soit resté 
similaire. L’utilisation du suivi myocardique basé sur la technique d’extraction du squelette 
myocardique devrait être examiné et pourrait ouvrir de nouvelles avenues pour une meilleur 
estimation des déplacements myocardiques, puisque la technique réduit considérablement le 
phénomène de glissement et est basée sur les caractéristiques géométriques du myocarde. 
Cependant, plusieurs limites doivent être traitées comme par exemple le fait que le mouvement à 
travers le plan ne soit pas considéré. Le fait d’inclure ce mouvement dans notre modèle pourrait 
permettre une évaluation quantitative des déplacements du myocarde. 
Notre nouvelle technique pour estimer les contraintes et déformations myocardiques donne des 
résultats robustes et un suivi précis du tissu myocardique. Les contraintes et déformation étaient 
évaluées en utilisant soit la technique linéaire soit la technique cumulative. Les deux techniques 
donnent une estimation indépendante des contraintes et déformations qui peut être utilisée pour 
détecter tout changement dans la fonction mécanique du myocarde. Encore une fois, dans la même 
cohorte de survivants de cancer, les contraintes et déformations myocardiques étaient 
significativement plus faibles par rapport aux volontaires sains, ce qui pourrait indiquer une 
réduction de la fonction contractile du myocarde. L'utilisation des contraintes et déformations 
apparentes devrait apporter de nouveaux renseignements en termes de la fonction mécanique du 
myocarde qui doivent être explorés. 
Pour conclure, pour le moyen et long terme, ce projet contribue à l'avancement des connaissances 
dans le domaine des cardiomyopathies induites par la doxorubicine, le suivi du myocarde et 
l'analyse multiparamétrique du myocarde. En outre, les techniques présentées dans cette étude pour 
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la détection précoce des cardiotoxicités induite par la doxorubicine sont toutes prometteuses. Nous 
croyons que tous les indices présentés ont leur mot à dire dans la détection des cardiotoxicités 
induite par la doxorubicine. Toutefois, la technique des patrons de déplacement est considérée 
comme étant la plus susceptible de détecter précocement les cardiotoxicités induite par la 
doxorubicine. 
 
viii 
ABSTRACT 
Doxorubicin chemotherapy is effective and widely used to treat acute lymphoblastic leukemia. 
However, its effectiveness is hampered by a wide spectrum of dose-dependent cardiotoxicity 
including both morphological and functional changes affecting the myocardium. Currently, very 
few techniques are available for detecting such cardiotoxic effect. The use of muscle fibers 
orientation (e.g., diffusion tensor imaging DT-MRI) or 3D imaging techniques (e.g., cine DENSE 
MRI) are possible alternatives, however, their clinical application is limited due to the acquisition 
time and their estimation errors.  
In contrast, the use of multi-parametric MRI along with cine MRI is a promising alternative, since 
theses techniques are already available at a clinical level. Multiparametric MRI including T1 and 
T2 imaging may be helpful in detecting myocardial tissue damage, while cine MRI may be more 
appropriate to detect functional changes within the myocardium. The combination of these two 
techniques may further allow an extensive characterization of myocardial tissue function.   
In this doctoral project, the use of pre- and post-gadolinium T1 and T2 relaxation times is firstly 
assessed and proposed to detect myocardial damage induced by doxorubicin chemotherapy. 
Secondly, the use of 2D myocardial displacement patterns is assessed in detecting myocardial 
damage and functional alteration due to doxorubicin-based treatment. Finally, the use of finite 
element modeling including mechanical strains and stresses to evaluate mechanical properties 
changes within the myocardium is alternatively proposed, assuming that doxorubicin-based 
treatment induces significant changes to both myocardial tissue morphology and function.  
In our cohort of cancer survivors, local myocardial changes were found between standard risk and 
high risks group using pre-gadolinium T1 relaxation times. These changes were further amplified 
with gadolinium enhancement, as confirmed by the use of partition coefficient, suggesting this 
MRI parameter along with partition coefficient as candidates imaging markers of doxorubicin 
induced cardiomyopathy. The use of T2 on the other hand showed that the high risk group of cancer 
survivors had higher T2 relaxation times compared to the standard risk group and similar to 
reported values. Though, a larger cohort of cancer survivors may be required to assess the use of 
T1 and T2 relaxation time as possible indices for myocardial tissue damage in the onset of 
doxorubicin-induced cardiotoxicity.  
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Within the same cohort of volunteers that were assessed in this study, displacement patterns were 
significantly lower in cancer survivors compared to healthy volunteers, although the signature of 
displacement curves remained similar. The use of skeleton-based myocardial tracking should 
further be considered and may open doors to a better estimation of myocardial displacements since 
it significantly reduces the sliding phenomenon and relies on myocardial geometry characteristics. 
However, several limitations need to be addressed such as the through-plane motion in order to 
allow quantitative assessment of myocardial displacements.  
Our new technique for estimating myocardial strains and stresses provided robust results and 
accurate tracking of myocardial tissue. Myocardial strains were assessed using either a linear-based 
or cumulative-based estimation of strains and stresses. Both techniques provided independent 
estimation that can be used to detect any alteration within the myocardial contractile function. 
Again, within the same cohort of volunteers, the apparent strains and stresses were significantly 
lower compared to healthy volunteers, which may indicate a reduction in myocardial contractile 
function. The use of apparent strains and stresses should further bring new insights in terms of 
myocardial mechanical function which needs to be explored.  
To conclude, for the medium and long term, this project contributes to the advancement of 
knowledge in the field of doxorubicin-induced cardiomyopathies, myocardial tracking and 
multiparametric analysis of the myocardium. Furthermore, the presented techniques for detecting 
doxorubicin-induced cardiotoxicity are all promising. We believe that all of the presented indices 
may have a say in detecting doxorubicin-induced cardiotoxicity with displacement patters analysis 
being the most susceptible to early detect doxorubicin-induced cardiotoxicity. 
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CHAPTER 1 INTRODUCTION 
Doxorubicin, belonging to the anthracycline family is a chemotherapeutic agent used for the 
treatment of many types and forms of cancer including leukemia, lymphomas, osteosarcomas, soft 
tissue sarcomas and breast, lung, bladder, endometrium, uterus, stomach and thyroid cancers [1]. 
It is normally administered by rapid intravenous doses [2, 3], and is believed to reside between the 
DNA strands of cancerous cells to further inhibit macromolecules synthesis and topoisomerase II 
progression [4].  
In the case of acute leukemias, the major problem related to doxorubicin chemotherapy lies in its 
cardiotoxic effects that depends mainly on the administered cumulative dose [5-7, 2, 8-10]. This 
cardiotoxicity affects not only molecular mechanisms, but also regional and global cardiac 
function. With current treatments, very few of these cardiotoxic effects appear reversible while the 
majority of them are not.  
1.1 Cardiotoxicity of doxorubicin 
In terms of molecular mechanisms, the main cardiotoxic effects at short-term, induced by moderate 
to high cumulative doses of doxorubicin, include: reactive oxygen species (ROS) generation [11-
13], lipid peroxydation of mitochondrial and sarcoplasmic membrane [14-18], calcium 
homeostasis alterations [19-21], iron (Fe3) homeostasis alteration [22-24], induced cellular 
apoptosis through signaling and ROS generation [25-27]. In terms of histologic changes, the 
cardiotoxic effects include: extracellular matrix disorganisation [28, 4], induced diffuse fibrosis 
[21, 4], muscle fibers and cardiomyocytes number decrease [5, 29, 30], mitochondrial swelling and 
myofibrillar Z-lines irregularity [5]. On the other hand, the cardiotoxic effects in terms of 
electrophysiological changes include: sinus tachycardia [31, 2], QRS-T signal amplitude drop [5, 
28] and premature ventricular contraction [31, 32, 4]. Finally, the cardiotoxic effects in terms of 
morphological and functional alterations include: ventricular systolic function decrease [33, 34, 8, 
4], ventricular dilatation and myocardial wall thinning [7, 4] and ventricular contractile function 
along with radial deformation decrease [7] [35, 4]. 
Several histological changes (Figure 1.1) in the myocardium are related to doxorubicin-based 
therapy. Druck et al. (1984) reported the presence of 68% of patients with histological grade of 1.0 
or more following administered doxorubicin doses above 200 mg/m2 [32]. In addition, several other 
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histological observations are described including: loss of muscle fibers and increased interstitial 
tissue along with altered syncytial arrangement of muscle fibers [5, 35], presence of diffuse fibrosis 
and myofibrilar loss [28, 4, 30], myocyte vacuolization [29] and mitochondrial loss with 
myofibrilar structure disorganization [21]. Most cardiomyopathies are reported in the left ventricle 
as it is the most studied cardiac chamber. However, there are currently no proposed models in the 
literature to assess doxorubicin-induced cardiotoxicity to our knowledge. 
 
Figure 1.1: Myocardium histologic slice from a rat treated with doxorubicin. Masson’s trichrome 
stain at the mid-ventricular level in control rats (A et C) compared with rats pre-treated with 
doxorubicin (B et D). Note the presence of interstitial and perivascular fibrosis (blue stain) in pre-
treated rats (adapted from Migrino et al., (2008) [35]). 
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Furthermore, most of doxorubicin-induced cardiotoxic effects are progressive and occur during the 
first 6 months after the last treatment [34]. Their amplitude depends mostly on the cumulative dose 
of doxorubicin, usually measured in milligrams per square meter of body surface area. Some 
changes occur early while other take several weeks or even months to manifest, and at this stage 
become irreversible by current treatments [36]. In addition, the contribution of these 
cardiotoxicities to cardiac dysfunction and myocardial tissue damage in children is not well 
understood, considering that current clinical indices can only detect important tissue damages [35, 
37, 38].  
 
Figure 1.2: Molecular structure of doxorubicin and its analogues (DOX: doxorubicine, DNR: 
daunaurubicine, EPI: epirubicine, IDA: idarubicine) of the anthracycline family (adapted from 
Minotti et al. (2004) [39]). 
 
On the cardiac function part, chemotherapeutic treatment with doxorubicin (molecule displayed in 
Figure 1.2) induces several changes in cardiac function. According to the cumulative dose 
administered, these changes include: increased heart rate [40], diastolic pressure and heart mass 
[28], dilatation of the ventricular myocardium [28, 4], increased myocardial wall stress, ventricular 
diastolic dysfunction [7, 4], reduced ejection and shortening fractions [33, 34, 8, 4], decreased 
radial contractility [35, 41] and sometimes induced heart failure [5, 9]. 
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1.2 Cardiomyopathies diagnosis 
Doxorubicin seems to alter both functional and biochemical parts of the heart. Although 
mechanisms behind their action remain uncertain, diagnosing them early is crucial to prevent future 
progressive degeneration of the heart tissue and its function. Current gold standard for the diagnosis 
of doxorubicin-induced cardiomyopathie remain endomyocardial biopsy of both the left and right 
ventricle [42, 43]. However, the main drawback of myocardial biopsy is that it is invasive. Non-
invasive techniques include 12-lead electrocardiogram, echocardiography and MRI [44, 45]. While 
MRI is often the gold standard within non-invasive techniques, echocardiography remains the most 
used tool to diagnose doxorubicin-induced cardiotoxicity. Exercise-spirogometry and stress-
echocardiography [45] have also been proposed as possible biomarkers to detect late cardiotoxicity. 
On the other hand, the use of contrast enhancement agents in MRI is also a promising alternative 
[46]. 
Furthermore, most of the reported studies use echocardiography to estimate myocardial 
displacements and characteristics in the context of doxorubicin-induced cardiomyopathies. 
However, the geometric assumptions behind echocardiography, which affect both the M mode and 
two dimensional echocardiography, may lead to inaccurate measurement of myocardial 
characteristics [47]. MRI on the other hand is considered as the gold standard within non-invasive 
techniques. It is not only non-invasive but also provides high-quality cardiovascular images which 
can be used to diagnose cardiomyopathies. MRI provides not only conventional cine MRI images 
which are used to extract myocardial displacement and other characteristic and functional 
parameters with high precision, but also other more specialized imaging sequences such as T1 and 
T2 relaxation times that can be used to detect alterations in terms of the biochemical contents of 
the myocardium. 
1.3 Thesis plan 
This thesis is presented by scientific articles. The rest is organized into seven chapters. First, 
Chapter 2 presents a review of literature of reported doxorubicin-induced cardiotoxicity. Chapter 
3 discusses the context, objectives and the main hypotheses of the thesis as well as the overall 
approach of the research work. The next four chapters are devoted to the original contributions of 
this thesis and correspond to the four articles published or in the process of submission. Chapter 4 
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includes the first article that reviews doxorubicin-induced cardiotoxicity, published in The 
international journal of cardiovascular imaging. Chapter 5 includes the second article, submitted to 
the Journal of Magnetic Resonance Imaging, which investigate the use of myocardial T1 and T2 
relaxation times as biomarkers for doxorubicin-induced cardiotoxicity. Chapter 5 includes the third 
article that investigates the use of myocardial displacements patterns using clinical cine MRI in 
doxorubicin-treated cancer survivors, submitted to the Journal of Cardiovascular Magnetic 
Resonance. Chapter 6 includes the fourth article that investigates the use of myocardial 2D strains 
and stresses in the detection of doxorubicin-induced cardiomyopathies, submitted to Medical 
Image Analysis. Chapter 7 proposes a general discussion of the overall work done during this 
project and finally the conclusion which discusses the contributions of this thesis, the new avenues 
of research to be explored and perspectives for future work. 
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CHAPTER 2 LITERATURE REVIEW 
In this chapter, a brief review of the literature on the heart and on the different methods we used to 
investigate doxorubicin-induced cardiotoxicity is presented. It is organized into four main sections. 
Section 2.1 covers some key aspects about the anatomy and physiology of the human heart that are 
relevant to understand how the heart is affected by doxorubicin-based chemotherapy. Section 2.2 
presents the pertinence of the use of MR parameters such as T1 and T2 relaxation times in the early 
detection of doxorubicin-induced cardiotoxicity. Section 2.3 presents the use of myocardial 
displacement patterns and their application in the context of early detection of myocardial damage 
induced by doxorubicin-based chemotherapy. Finally, section 2.4 covers the use of biomechanical 
indices such as mechanical strains and stresses and explains how they may be relevant when 
investigating the structural part of the cardiac function in the onset of doxorubicin-induced 
cardiotoxicity. 
2.1 Anatomy and physiology of the human heart 
The anatomy and physiology of the human heart play a key role in understanding the mechanisms 
related to the cardiotoxicity induced by doxorubicin-based chemotherapy. The main function of 
the heart, being to supply the human body in blood fluid, is mainly accomplished by the heart 
muscle, known as the "myocardium". Taking the left ventricle as a point of origin (see Figure 2.1), 
the oxygenated blood is propelled with a LV pressure of 140 mmHg (see Table 2.1), which allows 
the opening of the aortic valve and blood distribution to the human body. Once the blood runs 
through the body to perform its function, it returns through the inferior and superior vena cava 
where it passes through the right atrium before being propelled to the right ventricle through the 
tricuspid valve with a pressure approximately of 5 mmHg. When the right ventricle is filled (end 
of atrial systole / end of ventricular diastole), the ventricular myocardium contracts and pumps the 
blood to the lungs through the pulmonary valve with a pressure of approximately 15-30 mmHg. 
Once the blood passes through the pulmonary circuit to be oxygenated, it returns through the 
pulmonary veins, where it passes through the left atrium before being propelled, following the atrial 
contraction, to the left ventricle through the mitral valve with a pressure of about 12 mmHg. 
Afterwards, the same loop is completed for each cardiac cycle. Ventricular pressure and volume 
curves followed during a specific cardiac cycle are shown in Figure 2.2. 
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Table 2.1: Cardiac chambers and arteries systolic and diastolic pressure (adapted from 
Klingensmith, 2008 [48]). 
Compartment Pressure (mmHg) S/D 
superior/inferior vena cava. 3-5 
Right atrium  2-5 
Right ventricle  15-30/3-8 
Pulmonary artery 15-30/4-12 
Pulmonary vein  2-15 
Left atrium  6-12 
Left ventricle  100-140/3-12 
Aorta 120/80 
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Figure 2.1: Human heart anatomy in 4-chamber view (Adapted from Netter, 2010 [49]).  
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Figure 2.2: The cardiac cycle and pressure/volume curves. (1) atrial systole, (2) isovolumic 
contraction, (3) fast ejection, (4) reduced ejection, (5) isovolumic relaxation, (6) rapidly filling 
period and (7) reduced filling. (Adapted from Klabunde, 2011 [50]). 
 
In general, for each cardiac chamber, pressure and volumes curves (Figure 2.2) depend mainly on 
the input / output in terms of blood fluid, the geometry in which the fluid is confined along with 
the loading conditions which are represented mainly by myocardial contraction. The functional 
layers of cardiac tissue are the epicardium, myocardium and endocardium. The epicardium is 
comprised of connective tissue surrounded by epithelium which helps to limit the volumic 
expansion of the heart. The myocardium is composed of muscle fibers present in circular, oblique 
and helical forms and maintained by the fibrous skeleton. The arrangement of the cardiac muscle 
fibers is represented by two electrically isolated syncytia that are maintained by the skeleton: atrial 
syncytium and ventricular syncytium. The anchors and insertion point of the fibers is mainly 
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located in the cardiac fibrous skeleton which surround fibrous rings in peripheries of the valves 
except the tendinous cords, mainly found in the left and right ventricles. 
In parallel, the heart contracts due to an electrical impulse that propagates through atrial 
myocardium first (Figure 2.3), then through ventricular myocardium to initiate myocardial 
contraction. During each cardiac cycle, an electrical impulse is generated at the sinoatrial node, 
i.e., SA node, where it propagates through the atrial myocardium and stimulates it to trigger atrial 
systole. Once the impulse reaches the atrioventricular node, i.e., AV node, it is delayed by 
approximately 100ms (Figure 2.4), before being propagated to ventricular myocardium through the 
His bundle and until it reaches the Purkinje fibers. Afterward, ions would run freely between 
cardiomyocyte through gap junctions where they trigger cardiomyocyte contraction, i.e., 
ventricular systole. The time for electrical impulses to reach different myocardial regions is shown 
in Figure 2.4. 
  
Figure 2.3: Conduction system of the heart. Adapted from the Wikimedia Commons file. 
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Figure 2.4: Transmission of the electrical impulse through the heart (Adapted from Guyton and 
Hall, 2006 [51]). 
 
2.2 MR parameters: T1 and T2 relaxation times 
The use of T1, T2 and T2*relaxation times, also known as longitudinal and transversal spin-lattice 
relaxation times respectively, allows the detection of multiple tissue changes [52, 53], based on 
hydrogen proton spin relaxation in different tissues. Clinical T1 is used to detect the presence of 
diffuse fibrosis while T2 is used to detect the presence of cardiac ischemia [54] and T2* to detect 
myocardial iron overload [55]. The use of T1 and T2 can also be combined to give an indication in 
terms of water and fat contents in the imaged tissue. Recently, regarding the clinical use of MTR, 
Weber et al. showed that the presence of myocardial infarction was associated with the decrease of 
magnetization transfer ratio [56]. However, although combining these parameters seems to have a 
great potential in detecting early doxorubicin myocardial damage, clinical studies are still lacking 
in the literature. 
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2.3 Myocardial displacement patterns analysis 
Pattern analysis of myocardial deformation allows direct quantification of the cardiac function. The 
trajectory followed by the myocardium, from one phase to another during the cardiac cycle at each 
point can be quantified by a 2D or 3D vector. When the 2D or 3D myocardial wall deformation is 
followed during a cardiac cycle, a pattern with a specific signature is generated. However, in a 
pathological case where the architecture of cardiomyocyte fibers may be affected, these 
deformation patterns become altered and the damaged regions can be both localized geometrically 
and quantified in terms of 2D or 3D displacement amplitudes [35]. The advantage related to the 
use of myocardial displacement patterns obtained from cine MRI images is that we use the actual 
results in terms of myocardial deformation. Moreover, the distribution of displacements within the 
myocardium is directly mapped to myocardial geometry. Currently, very few tools are available 
for the analysis of 2D and 3D myocardial displacement patterns. Their use in the characterization 
and monitoring of cardiomyopathies has a great potential in understanding the pathological 
response of the myocardium during anthracycline-based chemotherapy but also in the development 
of cardio-protective treatments.  
The three main techniques used to track myocardial displacements of the human heart during a 
cardiac cycle  can be summarized as: the use of dedicated imaging sequences such as 3D cine 
DENSE which encode the 3D tissue displacement directly into the phase of the MR image (Hess, 
2009, Zhong 2010), the use of simulated fibers directions [57, 58] (see Figure 2.5 and 2.6) or 
obtained by specialized sequences such as ex vivo diffusion tensor magnetic resonance imaging 
DT-MRI [59, 60], and the use of reconstruction techniques based on 2D imaging combined with 
3D reconstruction [61-65] (see Figure 2.5 and 2.6). A concise review of several myocardial 
deformation tracking techniques including tagged, cine, phase contrast, DENSE and SENC MRI 
based technique was reported by Wang et al. (2012a) [66]. Although the mutual objectives are to 
allow the simulation of the cardiac cycle and to quantify myocardial tissue damage, currently, only 
the reconstruction-based technique allows clinical application, small reconstruction errors and 
guarantees realism in terms of simulations. 
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Figure 2.5: A: finite-element ventricular myocardium model obtained from cine- and DT-MRI 
(adapted from Sermesant et al. 2012 [61]). B: complete volumetric model of the human heart 
obtained from cardiovascular computed tomography data (adapted from Peters et al. 2009 [62]). 
 
Figure 2.6: A: parametric ventricular myocardium model including simulated fibers direction 
(adapted from Niederer et al. 2011 [57]). B: parametric left ventricular model obtained using 2D 
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control curves with computed tomography data (adapted from Wang et al. 2012 [63]). C: 
parametric ventricular myocardium model adjusted to echocardiographic data that allow 
independent loading conditions simulation (adapted from Aguado-Sierra et al. 2011 [67]). 
 
2.4 Biomechanical indices: strains and stresses 
Myocardium contraction is done through coupled electromechanical excitation [68], which with 
the contribution of anatomical architecture of cardiac muscle fibers, generates specific patterns of 
ventricular volumes and pressure curves. During a normal heartbeat, the cardiomyocyte changes 
about 20% of its length [69]. Moreover, the organization of muscle fibers bundles that are mainly 
found in circular, oblique and spiral disposition gives a unique geometrical deformation of the 
human heart. Among reported cardiotoxic effects induced by doxorubicin, many are suspected to 
induce changes in terms of muscle fibers structure, function and density. However, consequences 
on the myocardial mechanics’ part (structure and function) remain poorly understood and need to 
be addressed.  
Myocardial muscle fibers are 1.5-3 times stiffer in the fiber direction [70, 71]. However, it is 
important to recall that during experimental testing, where equibiaxial loading conditions are 
applied in a physiological range of strains, the difference between fiber and cross-fiber directions 
in terms of tensile strength is significantly smaller [72, 73]. Cross-fiber loading condition is applied 
naturally by intra-chamber resulting pressure or by loading in the fiber direction itself which result 
in interaction between the different fiber bundles, i.e., directions. Moreover, there are different 
types of fiber directions and their exact presence, depending on the myocardial segment, are 
currently unclear. In terms of stress-strain relation, another factor would be the extracellular matrix. 
Tensile failure of the porcine extracellular matrix is relatively the same in both fiber and cross-
fiber direction, whereas the tensile modulus is estimated 3 times stiffer in the fiber direction [74]. 
Consequently, modelling biomechanical (active and passive) myocardial parameters is a 
challenging task. Considering the whole myocardial structure with only myocardial fibers 
orientation and mechanical properties and omitting extracellular matrix properties may 
significantly impact the accuracy of the model. 
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CHAPTER 3 OBJECTIVES AND MAIN HYPOTHESES 
3.1 Context of doxorubicin-induced cardiotoxicity 
In the context of doxorubicin-induced cardiotoxicity, it is important to evoke the need to early 
detect myocardial damage induced by doxorubicin-based chemotherapy, especially in children 
where delayed cardiotoxicity may manifest years or decades after treatment. A major difficulty 
associated with the development of cardioprotective agents is related to the timing of the various 
cardiotoxic effects and the triggering mechanisms which currently remain unclear. Two questions 
related to this issue will be studied during this doctoral project: What cardiomyopathies are induced 
by doxorubicin-based chemotherapy that can be detected by MRI? and Do these doxorubicin-
induced cardiomyopathies alter the myocardial function? 
To answer these two questions, we will need to acquire cardiovascular images from cancer 
survivors and investigate them to explore the whole spectrum of anthracyclines-related 
cardiotoxicities on the myocardial tissue. Currently the cardiotoxicities that arise with 
anthracyclines-based treatment are not clear enough and the literature is lacking studies that 
investigate anthracyclines cardiotoxicity using cardiovascular magnetic resonance imaging (MRI). 
Our choice of using MRI instead of echocardiography or other imaging techniques relies on the 
fact that MRI remains the gold standard when it comes to investigating cardiomyopathies in 
general. On the other hand, MRI provides the most advanced imaging sequences such as cine MRI 
and T1 and T2 imaging susceptible to detect any alteration in the myocardium. For this reason, 
MRI was selected as the main imaging modality. 
3.2 Objectives and hypotheses 
In this context, the proposed objectives and hypotheses underlying this doctoral project are:  
1) Review doxorubicin-induced cardiotoxicity  
2) Evaluate MR parameters, including pre- and post-gadolinium T1 and T2 relaxation times, 
sensitivity to detect myocardial damage induced by doxorubicin chemotherapy. The 
assumption underlying this part of the project is that MR parameters (T1 and T2) are 
sensitive in the detection of doxorubicin-induced cardiotoxicity  
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3) I) Propose a quantitative method to estimate the effect of doxorubicin-based treatment in 
cancer survivors on myocardial displacement patterns using cine cardiovascular MR (cine-
CMR). The hypothesis underlying this part of the project is that doxorubicin chemotherapy 
induces direct damage to myocardial fibers architecture which can be detected through 
myocardial displacement patterns analysis.  
II) Evaluate clinical indices’ sensitivity to detect changes in the myocardial function (both 
systolic and diastolic) following doxorubicin chemotherapy. Thus, the assumption 
underlying this project is that clinical indices are sensitive in the detection of doxorubicin-
induced cardiotoxicity. 
4) Develop a method based on cine MRI associated to a finite element model of the 
myocardium to evaluate mechanical properties changes within the myocardium in children 
receiving doxorubicin therapy for leukemia. The main hypothesis underlying this part of 
the project is that doxorubicin treatment induces significant changes to myocardial 
mechanical properties, i.e., contractile function.  
An article is proposed for each objective (see Figure 3.1) and the long-term objective of this project 
is to develop new diagnostic tools to characterize early myocardial degeneration using the most 
sensitive imaging-based biomarker and the underlying hypothesis is that doxorubicin-based 
treatment induces important changes to myocardial function in children receiving doxorubicin-
based chemotherapy. 
The overall approach of this research work is based on acquiring cardiovascular images from acute 
lymphoblastic leukemia survivors, including cine MRI and T1 and T2 images and analyse them to 
extract myocardial characteristics. Firstly, cardiovascular T1 and T2 images will be acquired and 
segmented to extract myocardial T1 and T2 signal. This myocardial signal will further be analysed 
to determine whether T1 and T2 sequences are sensitive in the detection of doxorubicin-induced 
cardiotoxicity. Secondly, using cine MRI images, the myocardial area will be segmented to extract 
myocardial displacement patterns during the cardiac cycle. These patterns of displacement will 
further be analysed and compared between the different groups, i.e., cancer survivors at high risk, 
cancer survivors at low risk and healthy volunteers. Likewise, the effect of doxorubicin-based 
treatment on myocardial displacement patterns will also be investigated. Finally, using myocardial 
displacements obtained from cine MRI images, myocardial strains and stresses will be estimated 
using a hyperelastic finite-element model and compared between the different groups to determine 
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whether doxorubicin-based therapy induces mechanical properties changes in the same cohort of 
acute lymphoblastic leukemia survivors. 
 
 
Figure 3.1: Study diagram. 
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4.1 Abstract 
Doxorubicin chemotherapy is effective and widely used to treat acute lymphoblastic leukemia. 
However, its effectiveness is hampered by a wide spectrum of dose-dependent cardiotoxicity 
including both morphological and functional changes, affecting primarily the myocardium. Non-
invasive imaging techniques are used for the diagnosis and monitoring of these cardiotoxic effects. 
The purpose of this review is to summarize and compare the most common imaging techniques 
used in early detection and therapeutic monitoring of doxorubicin-induced cardiotoxicity and the 
suggested mechanisms of such side effects. Imaging techniques using echocardiography including 
conventional 2D and 3D echocardiography along with MRI sequences including Tagging, Cine, 
and quantitative MRI in detecting early myocardial damage are also reviewed. As there is a 
multitude of reported indices and imaging methods to assess particular functional alterations, we 
limit this review to the most relevant techniques based on their clinical application and their 
potential to early detection of doxorubicin-induced cardiotoxic effects. 
4.1.1 Keywords 
Anthracycline, Doxorubicin, Cardiotoxicity, Acute lymphoblastic leukemia, Childhood cancer. 
4.2 Introduction 
Doxorubicin chemotherapy is part of the standard treatment regimens for children with acute 
lymphoblastic leukemia [2]. However, its effectiveness is hampered by a wide spectrum of dose-
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dependent cardiotoxicity including morphological changes such as myofibril loss and diffuse 
fibrosis and several resulting functional changes such as progressive ventricular dysfunction and 
late congestive heart failure [4]. While mechanisms underlying doxorubicin cardiotoxicity remain 
uncertain [39], characterizing their effect on the myocardium would help not only diagnosing 
myocardial damages and monitoring future cardioprotective treatments, but would also bring 
insights as to which metabolic and regulatory pathways are involved. In this review, we will 
attempt to explore whether the current cardiovascular imaging techniques are sensitive enough for 
early detection and monitoring of doxorubicin-induced cardiotoxicity. We will also attempt to 
explore if the recent exploratory techniques are clinically relevant and feasible. 
The first section will describe the doxorubicin-induced dose-dependent cardiotoxicity including: 
histological findings, functional and morphological damage and incidence of late cardiotoxicity. 
The second section will review the proposed mechanisms underlying anthracycline-induced 
cardiotoxicity. The third section will review current imaging techniques, their potentials and their 
limitations to detect early changes preceding low cardiac output in doxorubicin-induced 
cardiomyopathy including 2D and 3D echocardiography as well as cardiovascular MRI. The last 
section will conclude on the relevance of cardiovascular imaging to detect doxorubicin-induced 
cardiotoxicity and its progression. 
4.3 Doxorubicin-induced dose-dependent cardiotoxicity 
The probability of a doxorubicin-induced congestive heart failure is related to the total dose of 
administered doxorubicin. The linear correlation between the probability of secondary 
cardiomyopathy and the cumulative dose starts at around 4% when the cumulative dose is 500–
550 mg/m2, and increases to 18% at 551–600 mg/m2, to 36% when it exceeds 600 mg/m2 [5], and 
up to 50% at a dose of 1000 mg/m2 [75, 76]. The difference between the lower and the upper 
therapeutic range is rather small, but the consequence of either side of this therapeutic range could 
be life-threatening [77], on one side by insufficient dose to complete remission and on the other 
side by excessive dose inducing potentially irreversible cardiotoxic effects. In a retrospective study 
of 4018 patients, early results yielded an overall incidence of drug-induced congestive heart failure 
of 2.2% [31]. Moreover, a weekly dose schedule of doxorubicin administration is associated with 
a significantly lower incidence of congestive heart failure than the 3-week schedule. Several 
clinical factors known to predispose for cardiomyopathy include age (>65 years), simultaneous 
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administration of other antineoplastic agents that are damaging to the myocardium, method of 
doxorubicin administration, previous cardiac disease and combination of multiple therapies [2, 28, 
78]. Nevertheless, characteristics such as patient’s ability to carry on normal activities, sex, race, 
and tumor type were not risk factors [31]. Moreover, some patients may tolerate higher doses than 
the acceptable threshold [76], while others may experience late cardiotoxic effect at even low doses 
[79], suggesting other factors, such as genetic predisposition, may play in individual response to 
the therapy. The pharmacokinetics of doxorubicin remain variable between patients. In children, 
body surface area is preferred to body weight or lean body mass for dose normalization. 
Notwithstanding, inter-patient dose variation results in up to 5-fold of the maximum doxorubicin 
plasma level in children [77]. 
The genetic factor may also explain the inter-individual variations in the cardiac response to 
doxorubicin treatment. Although the topic has not been extensively studied [80, 81], there is an 
advocated need to assess genetic predispositions to doxorubicin cardiotoxicity [82, 80, 81]. 
Carbonyl reductase (CBR) mediated reduction of anthracycline to cardiotoxic alcohol metabolite 
is believed to be a major metabolic route implicated in the pathogenesis of cardiotoxicity [83, 84]. 
Patients with CBR3 V244M homozygous G genotype are at an increased risk of cardiotoxicity at 
doses as low as 101-150 mg/m2 [84]. Other genes polymorphisms such as in GATA-4 [85] or 
histamine N-ethyl transferase [86] may also be important in the assessment of individuals 
predisposition to doxorubicin cardiotoxicity. However, as reactive oxygen species generation and 
subsequent lipid peroxidation could be responsible for most if not all subsequent events including 
alterations in gene expression [87], knowing the relative timeline of the genetic factor relative to 
reactive oxygen species generation is crucial. 
4.3.1 Histological findings 
Chemotherapy induced cardiomyopathy has been studied invasively with endomyocardial biopsy. 
Accordingly, at cumulative doses exceeding 200 mg/m2, 68% of patients had Billingham (modified 
scale) biopsy grades of 1.0 or higher with no correlation between the cumulative dose and the 
biopsy grade [32]. The presence of areas with patchy myocardial interstitial fibrosis and scattered 
vacuolated myofibrillar loss [28, 4], a loss of muscle fibers and an increase in the amount of 
interstitial tissue as well as the disruption of the syncytial pattern seen in normal myocardium were 
noted [5]. The presence of vacuolization of cardiomyocytes and edema (Figure 4.1) as early as 24 
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h after a single injection of 2.5 mg/kg in rats along with condensation of the nucleus, shrunken 
appearance of the cardiac myocyte, gradual dose-dependent decrease in the staining intensity and 
disorganization of cross-striated staining patterns were also observed [29]. Enlarged T-tubules and 
distension of the sarcoplasmic reticulum with disarray and mitochondrial loss were demonstrated 
in rats previously treated with doxorubicine, while higher cumulative doses were associated with 
mitochondrial degeneration, myofibrillar disarray and edematous cardiomyocyte with even the 
absence of subsarcolemmal mitochondria [21]. Interestingly, interstitial and perivascular fibrosis 
[35] at midventricular level in rats myocardium were reported, suggesting the presence of both 
extra- and intracellular mechanisms. Early changes may also include signs of dose-dependent 
inflammatory cells infiltration and myocardial fibrosis [30]. However, most of these histologic 
findings are associated with relative high cumulative doses, although, they may appear at much 
smaller doses in the absence of measurable cardiac dysfunction [88]. 
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Figure 4.1: Histologic section of rat myocardium. a) Control. b) 24 h after a single injection of 2.5 
mg/kg. c) TUNEL-positive nucleus at 24 h post injection of 2.5 mg/kg. d) Double staining with 
antimyosin. e) Control rat myocardium. f) Myocardium after a single injection of 2.5 mg/kg. g) 
Myocardium after a cumulative dose of 15 mg/kg.[Adapted from Arola et al. (2000)]. 
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4.3.2 Functional and morphological changes: effects on the cardiac pump 
Most patients experiencing anthracycline-associated cardiotoxicity show evidence of cardiac 
dysfunction within the first 6 months after therapy [34]. Early dose-dependent functional changes 
of the cardiac pump are witnessed clinically and at necropsy including: increased heart rate [40], 
increased diastolic blood pressure and heart weight, abnormal systolic time intervals [28] and 
ventricular dilatation [28, 4]. The electrocardiogram may reveal initial arrhythmia, most commonly 
sinus tachycardia [31, 2], nonspecific ST-T changes [31, 32, 4], left axis deviation and non-
sustained supraventricular tachycardia with premature atrial and ventricular beats [4], decreased 
amplitude of QRS complexes [5, 28], premature ventricular contraction, as well as features 
suggestive of myocardial infarction [31]. Cardiac ventricular function changes in both animal and 
human studies include diastolic dysfunction with wall stress increase and wall thickness 
dysfunction [7, 4], fractional shortening and ejection fraction decrease [33, 34, 8, 4], reduction in 
radial strain (transmural profiles amplitude of myocardial strain in the radial direction of the left 
ventricle) associated with histologic indices of myocardial injury [35], progressive effect in 
reduced contractility and increased afterload [89] and congestive heart failure [5, 9]. 
4.3.3 Late toxicity incidence 
When myocardial damage involves a critical mass of cardiomyocytes, the heart expands in size 
and the chamber walls become thinner which lead to a dilated cardiomyopathy with reduced 
contractile function [90]. The acute form of doxorubicin cardiotoxicity may manifest itself within 
24 h of infusion, while chronic cardiotoxicity may take as long as 4 to 20 years at post-treatment 
[91]. While most doxorubicin cardiotoxicity occur within the first 6 months after therapy, patients 
developing late doxorubicin-induced cardiomyopathy seem to have milder cardiac decompensation 
and better chances for functional improvement [34]. In a long term echocardiography follow-up of 
acute lymphoblastic leukemia survivors treated with either 180 or 240 mg/m2 of anthracycline, no 
clinically relevant cardiac damage was tangible. In contrast, subclinical abnormalities were 
described mostly by a decrease in the isovolumetric relaxation time and Tei-index of the left 
ventricle 13.3 years following treatment [92]. With cumulative doses under 450 mg/m2, the 
diagnosis and monitoring of late cardiotoxicity remains important even beyond the first year after 
of follow-up [35], especially in the pediatric and young adult population [93, 94, 79, 33]. Overall, 
it is agreed that the cumulative loss of mature cardiomyocytes leads to heart failure because of a 
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very limited proliferative potential during a life time [95]. Hence, early detection of cardiac toxicity 
may be essential for establishing early intervention for better outcome. 
4.4 Mechanisms underlying anthracycline-induced cardiotoxicity 
Mechanisms (Table 4.1) behind doxorubicin-induced cardiotoxicity are still uncertain. Numerous 
evidence suggest a signaling pathway involving reactive oxygen species generation and lipid 
peroxidation, perturbation of calcium handling, inhibition of gene expression [95] and induced cell 
death through both apoptosis and necrosis [96]. 
Table 4.1: Mechanisms underlying Anthracyline-induced cardiotoxicity. 
Proposed mechanism 
Induced 
cadiotoxicity 
Reported changes Description 
ROS generation and lipid 
peroxidation [11-13, 97] 
Membrane lipid 
perooxidation 
↑ NADPH oxidation level 
↑ TBARS concentration 
 
Detected as early as 1 h 
Mitochondrial damage 
[14-18] 
Cardiomyocyte 
dysfunction 
Mitochondrial membrane 
potential reduction 
 
Early effect 
ROS generation dependant 
Detected as early as 5 min 
post-treatment 
 
Inhibition of DNA and 
protein synthesis [98] 
 
- Early and late DNA damage 
patterns 
Dose-dependent DNA 
damage 
 
Apoptosis and Necrosis 
[25, 26, 97, 27] 
Acute 
cardiomyopathy 
Myocardial damage 
Caspase-3 activation 
Inhibited by antioxidants 
↓ membrane integrity 
 
P53 independent 
Detected at few hours post-
treatment 
Perturbation of Ca2+ 
handling [19-21] 
Reduced 
contractility 
SR Ca2+ release channels 
alteration 
↓ [3H]Ryanodine binding 
↑ SR Ca2+ release rate 
↓ mitochondrial calcium loading 
Results from ROS 
generation 
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4.4.1 Reactive oxygen species generation 
Reactive oxygen species are generated in a redox cycle, in addition to metabolic pathways for 
elimination, by a univalent reduction of doxorubicin to a semiquinone radical which can rapidly 
auto-oxidize in the presence of oxygen to generate superoxide anions [14]. Reactive oxygen species 
generation may alter many components of the cardiomyocyte near their site of generation, 
including membrane lipids, mitochondria and nucleic acids. The presence of anthracycline-induced 
lipid peroxidation was demonstrated [11, 12]. Adryamicin induced 30%-50% concentration 
increase of lipid peroxidation byproduct assessed using thiobarbituric acid reactive substances level 
in rats during 1 to 24 h post-treatment with a cumulative dose of 15 mg/kg [13] while more than 2-
fold increase in mice treated with a higher cumulative dose of 25 mg/kg [99]. A long-term oral 
administration of nitrate, between 7 days pre-treatment and 5 days post-treatment with 
doxorubicin) decreased significantly the malondialdehy and 4-hydroxyalkenals concentration 
levels in mice [100, 101, 18]. Moreover, the resulting changes were reversed by the use of 
antioxidants such as FP15 [99] and Probucol [13] which interestingly does not seem to interfere 
with antitumor activity of anthracycline. However, a common limiting factor in these studies 
resides in the limit of the assay sensitivity and specificity to quantify lipid peroxidation that remains 
hitherto controversial [102]. 
Mitochondria, representing 25% to 35% of the cardiomyocyte volume, are believed to be the 
primary targets in Adriamycin cardiotoxicity [14]. Several mitochondrial enzymes such as NADH 
dehydrogenase, cytochrome P-450 reductase and xanthine oxidase are involved in generating 
oxygen free radicals [103-106]. Mitochondrial damage, based mainly on reactive oxygen species 
generation, is demonstrated by numerous studies [15-18]. Very low concentration of doxorubicin 
induced mitochondrial membrane potential reduction which was followed by apoptosis within 
approximately 6 h [15]. Interestingly, superoxide production in mitochondria was seen as early as 
5 min within doxorubicin treatment followed by a release of the pro-apoptotic protein cytochrome 
c [15]. In the neonatal rat ventricular cardiomyocyte, reactive oxygen species generation was 
localized in the mitochondria  associated to a decrease in mitochondrial and MnSOD activity with 
increased cardiomyocyte death and mitochondrial membrane depolarization, changes that were 
reversed by the antioxidant and stilbenoid Rasveratrol [16]. Moreover, mitochondrial damage was 
seen in tumor cell line MTLn3 but not in H9c2 cells [17], which raise great concern about the 
different signaling mechanisms and development of further cardioprotective agents. Doxorubicin 
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strongly downregulated the stable expression of the cytochrome c oxidase subunits II and Va, while 
Mito-Q, a mitochondria-targeted antioxidant, restored them [107]. Long-term oral administration 
of nitrate in mice significantly reduced mitochondrial complex I and hydrogen peroxide H2O2 
generation and partially restored the cardiac function [18]. Conversely, the study did not investigate 
the interference of the agent in tumor cells. 
Inhibition of nucleic acid and protein synthesis is also a potential consequence of anthracycline-
induced reactive oxygen species generation [39]. At clinically relevant concentration of 
doxorubicin, two different DNA damage patterns were present in rats cardiomyocyte cell line H9c2 
[98]. The first one occurs early and may be completely repaired within two hours, while the second 
is seen within several hours and may be responsible for p53 activation. Interestingly, chemical 
inhibition of p53 prevented cell death but not DNA damage, which is in concordance with the p53 
being activated only when DNA damage exceed repair capacity. 
4.4.2 Apoptosis 
Apoptosis is the second main mechanism and is believed to be responsible for myocardial damage 
[108, 109, 25]. The mechanism is not involved in chronic cardiomyopathy [96] and is believed to 
induce acute rather than progressive chronic cardiomyopathy [29]. Furthermore, different 
regulatory mechanisms may be activated depending on the cumulative dose of doxorubicin [26]. 
Caspase-3 activity increases significantly in rats cardiomyocyte incubated with Doxorubicin [25]. 
On the other hand, Caspase-3 activation was significantly reduced when the cardiomyocyte was 
pre-treated with the metalloporphyrin antioxidant FeTBAP. The study suggested that apoptosis 
was induced by a H2O2-mediated mechanism that is independent of p53 activation [25] which is in 
agreement with previous studies asserting that the downstream effectors in apoptosis can also be 
activated independent of p53 [110]. Caspase-3 activity increase in H9c2 cardiomyocyte cell line 
was maximally detected 8 h after doxorubicin addition and preceded significant sub-G1 cells 
increase detected at 72 h, whereas elevation in reactive oxygen species generation was detected as 
early as 1 h post-treatment [97]. Fortunately, differences in terms of kinetics and order of 
mechanisms triggeing events between toxicity in tumor cells and cardiomyocyte are suggested, 
especially in the mitochondrial transmembrane potential and mass changes during treatment [17]. 
Doxorubicin induced different apoptosis mechanisms in normal (H2O2-dependant) and tumor (P53-
dependant) cells [25] while  doxorubicin along with daunorubicin led to immediate loss of 
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membrane integrity and resulted in cell death via necrosis, but not through apoptosis as assessed 
by caspase activity [27]. However, apoptosis happened only at high doxorubicin doses while lower 
doses are more likely to induce cell death through mitotic catastrophe [26]. The process order was 
reactive oxygen species formation, mitochondrial membrane depolarization, cytochrome c release, 
caspases-3 activation, followed by DNA fragmentation [110], which is in concordance with 
cardiomyocytic apoptotic mechanisms. However, at this point, no study confirmed the time course 
of doxorubicin-induced apoptosis in the cardiomyocyte. 
4.4.3 Anthracycline-induced alteration of calcium handling 
The last but not least mechanism is related to anthracycline-induced alteration of calcium handling 
[39, 111]. Early results in rabbits pre-treated with doxorubicin demonstrated a dose-dependent 
increase in the probability of open-state of the SR Ca2+ release channels [112], a decrease in the 
amount of SR Ca2+ release channels and [3H] Ryanodine binding [113], or an  increased SR Ca2+ 
release rate and decreased in vitro contractility of the cardiomyocyte, particularly after resting 
intervals [20]. The mRNA expression levels decreased for proteins responsible for Ca2+ uptake 
(SERCA2) and release (ryanodine receptor) [19]. Proteins that regulate the influx and efflux of 
Ca2+ across the plasma membrane remained stable however, and no extensive damage was seen at 
histology with the corresponding dose. Alterations in Ca2+ are suggested by these studies to result 
commonly from anthracycline-induced reactive oxygen species generation, mainly at the 
mitochondrial level [114]. Such alterations are important to the cardiac function since Ca2+ 
homeostasis is closely related to the cardiomyocyte contraction [115]. The most common site 
resulting in perturbation of calcium handling is the sarcoplasmic reticulum [19, 20], which includes 
one of the main calcium channels, the SR Ca2+-ATPase. Calcium dysregulation may be both a 
result and a cause of reactive oxygen species generation [116]. On the other hand, doxorubicin-
induced cardiac dysfunction can occur in the presence of impairment of RYR2 mRNA expression 
level but also in the absence of significant dysfunction to SR Ca2+ loading ATPase [117]. RYR2 
expression, thought mRNA levels, protein concentrations and Bmax, was also correlated to the 
decrease in left ventricular fractional shortening at echocardiography [117]. Correlations were 
further found between decreased mitochondrial calcium loading capacity and cumulative 
doxorubicin dose in rats [21]. Nevertheless, the triggering event in the suggested doxorubicin-
induced Ca2+ homeostasis perturbation and implication of other potential channels such as 
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mitochondrial Ca2+ uniporter and the plasma membrane Ca2+ ATPase is unclear. Whether these 
mechanisms are precursors or directly resulting from doxorubicin treatment is a question that 
remains open. 
4.5 Imaging techniques 
The “gold standard” for the detection of acute doxorubicin myocardial damage remains 
endomyocardial biopsy of the right ventricle as it provides the greatest reliability and sensitivity 
[118, 2, 43]. Endomyocardial biopsy is also used to grade the severity of doxorubicin-induced 
cardiotoxicity [103, 119, 120]. However, the disadvantage of this technique is that it is invasive, 
with inherent risks requiring experience and appropriate training [4]. On the other hand, the 
standard non-invasive screening includes 12-lead electrocardiogram at baseline and at the end of 
therapy despite its limited capacity to detect early toxicity with certainty [44]. These two methods 
represent the two edges of the “screening” spectrum and are limited by the invasiveness of the first 
and the lack of diagnostic power of the second. Hence, other screening means have been used in 
an effort to validate potential cardioprotective agents [121] but are known to lack sufficient 
predictive power of patients at higher risk [122, 123]. 
4.5.1 Echocardiography 
Recent developments provided significant improvement to echocardiography image quality and 
recommendations for its use [124]. Echocardiographic measurements of left ventricular fractional 
shortening and ejection fraction have always represented the basic measurements in assessing 
anthracycline cardiotoxicity [45, 44], particularly in children [125, 4]. However, in the setting of 
anthraycline-induced cardiotoxicity, these indices may not provide the same sensitivity. In an 
echocardiographic study including 108 survivors of childhood cancer, measurement of ejection 
fraction had a sensitivity of 25% to detect fractions less than 50%, and a false negative rate of 75%, 
while 3D echocardiography had 53% and 47% respectively using MRI as a reference [126]. Despite 
the reported high prevalence of reduced ejection fraction and cardiac mass among the patients, 
even in low-dose anthracycline, a larger cohort is required due to the absolute number of patients 
with reduced ejection fraction and cardiac mass. Although, both 2D and 3D echocardiography may 
accurately estimate the ejection fraction and provide similar results to cardiovascular MRI, area 
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and volume measurement are known to be underestimated, particularly in the presence of dilated 
cardiomyopathy [127]. 
 
 
Figure 4.2: 2D radial strain analysis in a doxorubicin treated rat using echocardiography. a) At 
Baseline. b) At 12 weeks. c) Fractional shortening using anatomical M-mode.[Adapted from 
Migrino et al. (2008)]. 
 
Using high cumulative doses in rats resulted in a significant 2D Doppler radial strain reduction 
(Figure 4.2) at 8 weeks which was further associated with histologic indices of myocardial damage 
and directly related to cardiac mass while inversely related to caspase-3 activity [35]. Doppler 
derived strain and strain rate measurement provide higher sensitivity and specificity than the 
measurement of ejection fraction in detecting early myocardial abnormalities during doxorubicin 
treatment [128]. At two weeks, myocardial damage was induced, as confirmed by histologic 
examination and was only detectable by strain and strain rate measurements, whereas standard 
echocardiographic parameters (dimensional and ejection fraction measurements) and myocardial 
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velocities were able to detect only delayed changes [128], including fractional shortening detection 
at 12 weeks [129]. Interestingly, even if the inter- and intraobserver scores in 2D strain 
echocardiography may be poor to moderate in the two-chamber view, the reliability scores seems 
to provide high reproduction values in almost all views [130]. Nevertheless, based on left 
ventricular shortening fraction and ejection fraction measurements, routine echocardiograms do 
not represent the ideal surveillance as they rarely identify cardiac damage significant enough to 
impact therapeutic decisions [131] despite baseline echocardiography screening assessment prior 
to chemotherapy [132]. 
Beyond the systolic function, studying diastolic function parameters seems to provide an added 
value to echocardiography. In a preliminary study on adult patients treated with anthracycline 
cumulative dose of 211 ± 82 mg/m2, significant changes in the diastolic function were reported 
within 3 months after treatment, whereas at 3 years, more pronounced changes in both diastolic 
and systolic function were seen, using both conventional and tissue Doppler echocardiography 
[129]. Another study including a series of 28 patients treated with anthracycline (212 ± 15 mg/m2), 
echo Doppler quantification of the E-wave (mitral valve at early filling), A-wave (mitral valve 
during atrial contraction) and the ratio E/A demonstrated better detection potential than the 
common ejection fraction index [133]. Figure 4.3 shows a diastolic dysfunction with preserved 
normal systolic function in a patient following doxorubicin chemotherapy. 
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Figure 4.3: In this patient with normal myocardial systolic and diastolic function (a and b), features 
of diastolic dysfunction following doxorobucin chemotherapy are evidenced by mitral inflow 
velocity fusion of early and late phase filling (c and d).  Diastolic function was also evaluated by 
tissue Doppler analysis (E/E’ ratios) of the septal and lateral walls of the left ventricle (e and f), as 
demonstrated in this patient with reduced left ventricle relaxation leading to increased E/E’ ratios 
(g and h). a) Systolic function (ejection fraction 76.9%). b) Mitral inflow (E/A = 1.83). c) Preserved 
normal systolic function (ejection fraction 68.7%). d) Compromised  mitral inflow (E/A = 1.1) e) 
Normal lateral wall relaxation with E/E’= 9.04. f) Normal septal wall relaxation with E/E’= 9.64. 
g) Reduced lateral wall relaxation with borderline E/E’= 10.1. h) Reduced septal wall relaxation 
with increased E/E’= 14.6. 
 
Exercise echocardiography is known to be more sensitive to early subclinical changes [134, 45, 
135]. At 6 months post-treatment, exercise echocardiography on doxorubicin treated children is 
more sensitive to assess cardiotoxicity, while ECG and 24 h Holter monitoring are less sensitive 
[45]. However, the reported cumulative doxorubicin dose used in that particular study was 
relatively low. At 12 month post-treatment, exercise echocardiography on doxorubicin treated 
children is also more sensitive to reflect dose-dependent anthracycline subclinical abnormalities 
than conventional echocardiography [135]. Above all, ejection fraction and fractional shortening 
changes do not seem to be associated with cumulative dobutamine dose for anthracycline-induced 
cardiotoxicity detection, which raise concerns about the predictive power of these commonly used 
indices both in rest and stress condition [133, 136]. Similarly, and to compensate for the relatively 
limited utility of resting echocardiographic evaluation, dynamic evaluation has been proposed. In 
this perspective, a challenge test with dobutamine, a sympathomimetic agent, was demonstrated to 
enhance the detection of anthracycline-induced cardiotoxicity, especially in children [137, 133, 
136]. Systolic and diastolic changes were found in 85% of children over 2 years old previously 
treated with moderate cumulative doses of anthracycline [137]. Whereas at rest 26% of them 
showed increased wall stress, the detection rate rose to 52% during dobutamine stimulation. 
Similarly, exercise detection of anomalies seems to elucidate a degree of predisposition to future 
cardiac deterioration [137]. 
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Further echocardiographic indexes may also provide sensitivity to early anthracycline-induced 
cardiotoxicity such as the Tei-index, a Doppler based myocardial performance index, to evaluate 
the severity of myocardial combined systolic and diastolic dysfunction [138, 139]. Significant 
difference in the Tei-index between patients groups receiving either >200mg/m2 or <200mg/m2, 
while no significant differences in left ventricular ejection fraction and fractional shortening were 
observed [140]. The peak oxygen uptake (pVo2) and anaerobic threshold were significantly 
decreased in patients treated with anthracycline and exercise intolerance was further associated 
with increased Tei-index [141]. Changes in the Tei-index may also be useful for early 
cardiotoxicity detection. On 23 patients with hematological malignancies receiving doses below 
420 mg/m2, Tei-index variations significantly correlated with doses variations, but not with left 
ventricular ejection fraction variations [142]. 
Other echocardiographic techniques, such as 3D echocardiography may further enhance the 
performance of conventional 2D echocardiography [143]. For instance, left ventricular function 
and volume measurements seem to be better estimated in 3D compared to 2 D imaging [144]. Other 
enhancements could be brought by the use of contrast agents with optimized definition of the 
endomyocardium [145]. 
4.5.2 Magnetic Resonance Imaging 
Although echocardiography is inexpensive and readily available clinically, MRI remains currently 
an alternative method used for myocardial function and perfusion evaluation, as well as for tissue 
characterization [146, 46, 147]. To assess particular myocardial tissue alterations, Table 4.2 
summarizes some of the reviewed imaging techniques and their main limitations. 
Table 4.2: Use and main limitations of MRI and echocardiography in the characterization of the 
myocardium. 
Modality Sequence Description/Usage Limitations Ref. 
MRI T1, T2, T2* and 
MTR 
Tissue characterization Inter-patient analysis requires 
quantitative mapping. 
 
[148, 149] 
LGE Short examination times 
High contrast-to-noise ratio 
 
Requires intravenous contrast 
agent administration 
[148] 
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Molecular 
Imaging 
Myocyte apoptosis and necrosis 
 
- [150, 60] 
 
Cine Ventricular function assessment 
Volume, derived mass and deformation 
measurements 
 
Segmentation required [87] 
Tagging Intramyocardial deformation 
Ventricular torsion 
 
Limited tag time during cardiac 
cycle 
[151] 
Models and 
others. 
3D structural analysis 
Biomechanical parameters 
Post-imaging analysis 
Time consuming 
Requires post-processing 
calculations 
[152, 151, 
153, 154] 
Echocardio
graphy 
Linear M-Mode Reproducible 
High frame rates 
 
- [124] 
Tissue Doppler 
Imaging 
Performed in apical views to acquire 
mitral velocities  
Measure both systolic and diastolic 
function 
 
Not accurate as index of filling 
pressure in normal subjects 
[155] 
3D 
Echocardiography 
 
Measurement of RV volume parameters Volume underestimation 
Lack sensitive analysis tools  
[144, 143, 
127] 
Contrast 
Enhanced 
Echocardiography 
Improved visualisation of endocardial 
border 
Improved assessment of  LV structure 
and function 
Clinically recommended 
Requires contrast 
administration 
[145, 156] 
 
4.5.2.1 Conventional MRI 
Conventional cardiovascular MRI allows the measurement of basic cardiac function parameters, 
volumes and derived mass calculations in any cardiac axis and with relatively high spatial 
resolution, although some axis views may be more reproducible and time-efficient measurements 
[87]. Along with the use of post-processing techniques, conventional MRI may quantitatively 
measure both global and regional cardiac function (Figure 4.4), however it may not allow 
measurement of 3D intramyocardial deformation in contrast to Tagging MRI. During the cardiac 
cycle, the force generated by the myocardium includes two components: passive tension, which 
resides in the connecting filament protein that tends to restore the sarcomere length when it is 
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stretched, and active force, the force generated during electromechanical activation-contraction. 
Active force is generally associated with systolic function while passive force is associated with 
diastolic function and normally requires prior knowledge of the intra-chamber pressure. The use of 
basic indices such as the left ventricular ejection fraction, ventricular volumes and mass provides 
a reasonable indication of the cardiac function and morphological characteristics [148, 87, 46]. But 
more importantly, there may be a future role for quantitative MRI to document diastolic and 
interstitial functions of the myocardium [157, 158]. 
 
Figure 4.4: Cardiovascular MRI. Short axis analysis (left) using long axis views as a cross-
reference (right). [Adapted from Childs et al. (2011)]. 
 
4.5.2.2 Tagging, Cine DENSE and Cine MRI 
Whereas the heart undergoes complex but predictable motion patterns in the healthy setting, proper 
characterization of its motion remains an open and challenging research subject. The use of 
specialized sequences such as Tagging and Cine DENSE imaging will further advance our 
understanding of the myocardial 3D deformation patterns and facilitate future development of tools 
and applications that serve that purpose. A tagging-based model was proposed to measure passive 
diastolic function using a combination of tagging and diffusion tensors MRI with concurrent 
pressure recordings [151]. Although the model requires considerable acquisition time and a 
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combination of multiple data acquisition, such models would greatly help quantify myocardial 
damage severity since the 3D structure of the myofibers is inherently mapped within the 
myocardium volume. A 3D Cine DENSE sequence with spiral K-space data acquisition was also 
introduced recently to quantify myocardial strain that encode tissue displacement directly into the 
image phase [154]. However, the sequence is time consuming and requires previous data 
segmentation to calculate the Lagrangian displacement field. Recent development in atlas and tools 
areas provided further the possibility to run statistical analysis using cardiac atlas databases that 
could play an important role in phenotyping anthracycline-induced myocardial dysfunction [153, 
152]. Such models are useful in the presence of cardiomyopathies, especially as it remains unclear 
how both active and passive myocardial function components are affected by doxorubicin 
chemotherapy. 
Cine MRI may also be used in combination with 2D and 3D models to track myocardial 
displacements [159-161], which is a starting when evaluating myocardial function and structure. 
Using the Lagrangian tensor, Bistoquet et al. (2008) proposed an incompressible biventricular 
model to estimate the 2D Lagrangian strain within the myocardium. A weaker radial and 
circumferential strain was reported in patient with ventricular dyssynchrony [159]. A 3D model 
based on short-axis control curves fitted to myocardial walls was proposed [160]. The model seems 
promising not only in the estimation of myocardial mechanics, but also in providing a personalized 
reconstruction of diseased hearts with functional alterations. Several other models are proposed 
with different potentials and limitations, which are discussed in [162, 153, 163, 164]. However, 
one limit that is common to most Cine-based myocardial models is the inability of the imaging 
sequence itself to image intramyocardial deformation such as with Tagging MRI. In an ongoing 
work, the authors used a whole-heart Cine MRI to estimate myocardial 3D deformation using 2D 
curves tracking and 3D assembly with kriging interpolation (Figure 4.5). Future work will include 
validation of the resulting deformation data using Tagging MRI as a reference to estimate the 
model’s sensitivity to intramyocardial deformation changes. 
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Figure 4.5: Myocardial deformation tracking in a healthy subject. a) MR acquisition configuration. 
b) Myocardial deformation (interpolated at geometry’s nodes) at t = 40ms. 
 
4.5.2.3 Multi-parametric MRI 
The use of multiple sequences, each giving a unique contrast for a given tissue, through proton 
relaxation characteristics, gives MRI the potential to detect a wide-spectrum of abnormalities and 
pathological tissue changes. Recent development in cardiovascular MRI has made several 
sequences available clinically. The use of the relaxation times T1, T2, T2* (Figure 4.6) and 
magnetization transfer ratio (MTR) provide an array of detectable changes capability [52, 148] to 
characterize myocardial and vascular tissue through characteristics of proton (1H) relaxation and 
magnetization transfer. T1 mapping with or without late gadolinium enhancement provide a great 
sensitivity to detect myocardial fibrosis and may be acquired within a single breath hold [165, 166]. 
In a study including 25 patients with heart failure and 9 transplanted hearts, shorter post-contrast 
T1 times were reported (383 ± 17 ms in heart failure compared to 543 ± 32 ms in control subjects, 
p < 0.0001) and further correlated with collagen contents at histology (R = -0.7). Significant 
decrease of both pre- and post-contrast T1 times were also reported in both chronic and acute 
myocardial infarction, with more pronounced changes in acute studies [167, 168]. T2 imaging on 
the other hand was demonstrated to detect myocardial edema [169], ischemia and other conditions 
involving changes in the tissue’s free water contents [149]. Normal T2 values in the human 
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myocardium are 52.18 ± 3.4 ms and significant increase in T2 times were reported in patients with 
myocardial infarction [169]. However, T2 mapping may not be useful to detect cardiac amyloidosis 
[170]. The use of T2* may also detect early myocardial iron overload [55]. Quantitative T2* 
imaging was studied in twelve gerbils with iron dextran loading and the results showed a strong 
linear correlation (R2 = 0.94) between 1/T2* and cardiac iron [171]. Although, association with 
anthracycline cardiotoxicity may only be hypothesized at this point, myocardial T2* is a reliable 
and sensitive sequence for diagnosis and monitoring myocardial iron overload [172]. 
Magnetization transfer, on the other hand, offers a potential use for tissue characterization and 
detection of pathologies such as myocardial infarction and inflammation and where myocardial 
tissue structural integrity is affected. A decrease in MTR was observed in a preliminary study 
including 7 patients with infarcted myocardium (24.5 ± 9.2% compared to 33.0 ± 3.3%, P = 0.035) 
[56]. While these sequences may be acquired during a single breath-hold and provide quantitative 
imaging for inter-patient analysis, their sensitivity in anthracycline cardiomyopathies diagnosis has 
not been sufficiently investigated. Relationships between the intrinsic passive properties of cardiac 
[157] and musculoskeletal [158] muscles and MRI parameters were recently reported. It would be 
interesting to investigate such relations in the setting of anthracycline induced cardiomyopathies. 
 
Figure 4.6: Multi-parametric MR mapping in short-axis at the mid-ventricular level in a healthy 
subject. T1 (a), T2 (b) and T2* (c) relaxation time maps. 
 
Our group has developed a multi-parametric MRI protocol composed of a multiple inversion 
recovery turbo spin-echo sequence for T1 mapping, a multi-echo turbo spin-echo sequence for T2 
mapping, two gradient echo sequences (one with an off-resonance pulse applied at 1100Hz down 
to the free water proton resonance frequency and the other one without it) for MTR mapping and 
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a multi-shot spin-echo echo-planar-imaging diffusion-weighted sequence for the apparent diffusion 
coefficient (ADC) and fractional anisotropy (FA) mapping. Multi-parametric MRI protocol 
associated to principal component analysis is a promising tool for the indirect evaluation of cardiac 
muscle mechanical properties and should be useful to find biomarkers and predictive factors of the 
evolution of the pathologies. Our in vitro experiments will now allow us focused in vivo testing on 
healthy and infracted hearts in order to determine useful quantitative MR-based biomarkers. Based 
on our data it is possible now to perform longitudinal in vivo testing on ischemic and revascularized 
hearts. Future directions of our laboratory aim to better understand and develop novel quantitative 
MRI parameters as biomarkers of myocardial viability and potential prognostic scoring of 
myocardial relaxation and contraction. 
4.5.2.4 Contrast-enhanced MRI 
Molecular imaging of the heart tissue is also feasible by contrast magnetic resonance imaging 
[173]. It provides great potential for further assessment of other cellular damage induced by 
necrosis and apoptosis [150, 60]. Contrast enhanced MRI with left ventricular ejection fraction 
evaluation was used to study 21 patients treated with anthracycline [46]. At day 3 (Figure 4.7) of 
therapy, delayed contrast enhancement and decreased ejection fraction were detected, where most 
patients had less than 100 mg/m2 of anthracycline cumulative dose. Moreover, an increase of >5-
fold of contrast enhancement was further associated with a significant loss of ejection fraction of 
16% at day 28 of follow-up. The presence of delayed enhancement in 21 of 25 patients with 
hypertrophic cardiomyopathy was reported [174]. Delayed enhancement was detected in an ill-
defined patchy (77.4%) and focal nodular (22.6%) patterns [174]. Delayed enhancement MRI may 
be particularly useful for assessing myocardial fibrosis [175, 176]. Correlations were found 
between late gadolinium contrast enhancement MRI and the presence of endocardial fibrosis with 
mild interstitial myocardial fibrosis seen at histology [177]. 
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Figure 4.7: T1-weighted before (a and c) and after (b and d) contrast administration. Increased 
myocardial enhancement at 3 days following anthracycline chemotherapy (c and d) compared to 
Baseline images (a and b), with a prominent contrast enhancement within the septum (arrow). 
[Adapted from Wassmuth et al. (2001)]. 
 
Manganese-enhanced MRI is also promising in disorders involving calcium homeostasis. 
Manganese dipyridoxyl-diphosphate (MnDPDP) was recently used in imaging infarcted 
myocardium [178] and with T1 mapping to quantify Mn2+ concentrations and define regions with 
potentially altered Ca2+ homeostasis [179-181]. However, high infused doses may have adverse 
effects in serial monitoring, although no Mn2+ intoxication cases have been reported in patients 
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with myocardial infarction receiving a single dose of 10 μmol/kg [178]. Assessing the dynamic 
feature of Mn2+ response should provide valuable information related to Ca2+ homeostasis in 
doxorubicin-induced cardiomyopathies. Mn2+ follows the same Ca2+ influx pathway to reach 
intracellular space due to its similar chemical properties to Ca2+ [181]. Calcium enters the 
intracellular space via Ca2+ voltage-dependant calcium channels and perhaps a much smaller 
amount via Na+/Ca2+ exchanger [182]. Accumulation of the Mn2+ in intracellular cell is due to the 
influx being strong that the efflux which make Mn2+ a potential contrast agent in clinical imaging 
[180]. 
While many sequences hold an important potential in diagnosing and monitoring 
cardiomyopathies, some powerful sequences remain however at the research level due to the 
required long acquisition times, insufficient signal-to-noise or the complex post-processing 
computations, such as cardiovascular diffusion tensors imaging [59] and MR spectroscopy [183]. 
The use of MRI may help discriminate the induced pattern of ventricular dysfunction from other 
pathologies such as stress cardiomyopathy [146]. 
4.6 Conclusion 
A wide-spectrum of functional and morphological anthracycline-induced changes have been 
described. It is important to recognise the need of imaging tools to identify the etiology of cardiac 
dysfunction in the setting of chemotherapy treatment. But above all, early detection of myocardial 
damage and appropriate monitoring of cardiopretective therapeutic strategies need to be enhanced. 
Although, both MRI and Echocardiography provide several potential ways in assessing 
anthracycline cardiotoxicity, MRI has the ability to modulate the contrast in response to some 
specific mechanisms and provide high quality functional information that may target specific 
cardiotoxic changes. Currently, there are no formal recommendations for the use of cardiovascular 
magnetic resonance in the setting of dilated cardiomyopathies or other anthracycline-induced 
cardiotoxicities in clinical practice. Hence, research and development in this direction are 
necessary. 
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5.1 Abstract 
Purpose: Doxorubicin-based chemotherapy is effective and widely used to treat leukemia. 
However, its effectiveness is hampered by a wide spectrum of dose-dependent cardiotoxicity. We 
aimed to assess the use of T1 and T2 relaxation times as indices of myocardial tissue changes 
following chemotherapy. 
Materials and Methods: We prospectively assessed 26 acute lymphoblastic leukemia (ALL) 
survivors (25.0 ± 7.7 years old) who previously received doxorubicine-based chemotherapy with 
MRI acquisitions including pre- and post-gadolinium T1 and T2 sequences. ALL survivors were 
divided into two groups: high risk (HR, n=18) and standard risk (SR, n=8). Images were acquired 
at apical, mid-ventricular and basal levels. Partition coefficient, T1 and T2 were compared between 
ALL survivors and healthy volunteers (HV, n=9). 
Results: Partition coefficients were higher in HR or SR group as compared to HV group (p<0.001). 
Pre-gadolinium T1 was higher in HR group compared to SR group (p<0.01), higher in SR group 
compared to HV group (p<0.005), and higher in HR group compared to HV group (p<0.005). Post-
gadolinium T1 was lower in HR group compared to SR group. T2 was significantly higher in HR 
group compared to SR group (p<0.001). 
44 
Conclusion: Local myocardial changes were found between high risk and standard risks groups in 
terms of T1 and T2. The partition coefficient confirmed the presence of an abnormal perfusion 
function in ALL survivors. The use of T1 and T2 as indices for myocardial tissue damages in the 
onset of doxorubicin-induced cardiotoxicity should be more investigated. 
5.1.1 Keywords 
Relaxation times, T1 mapping, T2 mapping, partition coefficient, doxorubicin, cardiotoxicity, 
chemotherapy. 
5.2 Introduction 
Several cardiotoxic effects are induced by doxorubicin chemotherapy. Most of them occur during 
the first 6 months after the last treatment and are progressive [34]. Their amplitude depends mostly 
on the cumulative dose of doxorubicin, usually measured in milligrams per square meter of body 
surface area. Some changes occur early while others take several weeks or even months to appear, 
and may become irreversible despite current treatments [36]. Reported changes include the 
induction of reactive oxygen species [13], cellular apoptosis [26], diffuse fibrosis [21], premature 
ventricular contraction [4], extracellular matrix disorganization [103] and other dose-dependent 
cardiomyopathies that may affect the cardiac function [4]. In adults increased risk of developing 
late cardiotoxicity is reported and associated with advanced age [8]. Moreover, late cardiac 
dysfunction may begin with congestive heart failure [8]. However, in children, who could be 
expected to live many decades after cure of malignancy, impaired myocardial growth, increased 
left ventricular afterload and possibly a reduction in myocardial contractile function have been 
reported [41]. Moreover, myocardial abnormalities seem to be highly dependent on the cumulative 
doxorubicin doses in children [33]. In addition, the contribution of these cardiotoxicities to cardiac 
dysfunction and myocardial tissue damage in children is not well understood, considering that 
current clinical indices can only detect late tissue damages [37, 35]. In parallel, the use of 
cardioprotective agents such as Dexrazoxane is known to reduce the formation of free radicals 
[184], thus limiting damages to the myocardium. 
Current studies on the detection of doxorubicin-induced cardiotoxicity are mainly focussed on MRI 
and echocardiography, while echocardiography being the most reported as it is inexpensive and 
the most readily available clinically [185]. Although parameters such as left ventricular ejection 
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fraction or fractional shortening are conventionally used at a clinical level, these parameters are 
insensitive biomarkers of early doxorubicin damage [35]. Parameters such as radial and 
longitudinal strains [35, 186] and MRI-based parameters such as T1 and T2 relaxation times [185] 
seem to provide a better potential to early detect doxorubicin-induced cardiotoxicity. The use of 
T1 and T2 relaxation times allows detection of multiple tissue damages [52, 53], based on hydrogen 
proton spin relaxation in different tissues. Clinical T1 is used to detect the presence of diffuse 
fibrosis while T2 is used to detect cardiac ischemia [169, 187, 188]. The use of T1 and T2 can also 
be combined to give insight in terms of water and fat contents in the imaged tissue. The use of T1 
and T2 sequences was previously proposed [185, 177, 189-191], with contrast enhanced T1 
imaging being one of the most expected to early detect doxorubicin-induced cardiotoxicity [177, 
46]. However, one limitation to these studies is that none of them have investigated relaxation time 
within the whole myocardial area, including the right ventricle. 
Contour-based myocardial segmentation, which takes into account the whole myocardial area is 
more extensive and less prone to segmentation errors. Inclusion of a specific myocardial signal and 
exclusion of noise is automatically controlled through thresholding rather than manually 
controlling regions of interest. Manually segmenting regions of interest is prone to segmentation 
errors and more importantly may not provide full assessment of the signal distribution over of the 
myocardial tissue. Moreover, using myocardial skeleton curves, standard myocardial segments 
may also be automatically extracted and analysed. Thus, in this context, the aims of this study were: 
1) propose a contour-based estimation of T1 and T2 relaxation times based on the whole 
myocardial area and 2) evaluate T1 pre- and post-gadolinium enhancement and T2 relaxation times 
sensitivity to detect myocardial changes induced by doxorubicin-based chemotherapy in childhood 
ALL survivors. 
5.3 Methods 
5.3.1 Cohort of survivors 
According to the research protocol approved by the institutional Review Board (IRB), we 
prospectively included 26 ALL survivors from the PETALE study [192] and 9 healthy volunteers 
(HV) who gave their informed consent. The ALL survivors (mean age: 25.0 ± 7.7 years), 13 males 
and 13 females, had previously undergone a doxorubicin-based chemotherapy treatment for 
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childhood leukemia, following the Boston protocol (cumulative doxorubicin doses of 241 ± 97 
mg/m2). These ALL survivors were divided into two groups: high risk (HR, n=18) and standard 
risk (SR, n=8), based on the cumulative doxorubicin dose received during treatment, age at the 
beginning of the treatment and other clinical factors. 10 out of 18 HR survivors received 
dexrazoxane doses of 2749 ± 463 mg/m2 as a cardioprotective agent. The 9 healthy volunteers 
(mean age: 48.4 ± 12.4 years), 7 males and 2 females, underwent the same MRI acquisition 
parameters for pre-gadolinium T1.  
5.3.2 MRI acquisition 
The MRI acquisitions were performed on a Siemens Skyra 3T MR system using an 18-channel 
phased array body matrix coil. T1 and T2 images were acquired for each patient during multiple 
breath-holds and ECG-gated acquisitions. T1 sequence was acquired using a MOLLI sequence for 
T1 mapping [193] and a T2-prepared TrueFISP sequence for T2 mapping [169]. Post-gadolinium 
T1 were acquired using Gadovist as a contrast agent at 10-15 min post injection for the ALL 
survivors. Images were acquired at apical, mid-ventricular and basal levels with a pixel resolution 
of 1.4x1.4x8.0mm. The overall acquisition time including the 3-plan Localizer scan was 
approximately 30 minutes.  
5.3.3 Myocardial segmentation  
Myocardial contours were semi-automatically segmented using an interactive implementation of 
cubic Bezier curves. In short axis view, three curves were used to segment myocardial area: 
endocardial left and right ventricular curves and epicardial curve. In a second step, resulting 
contour curves were re-parameterized and normalized using a percentage length-based 
discretization of each curve. Myocardial signal was then extracted using a polygon-to-mask 
algorithm from Matlab functions that converts polygonal contours into myocardial masks. Finally, 
myocardial skeleton was computed using a Binary-to-skeleton algorithm [194], which was further 
used to divide the myocardium into 20 segments using a modified version of the standard 17-
segment AHA model (Figure 5.1) that include the right ventricle. Segments positions (Figure 5.1) 
were limited using skeleton junction points and skeleton curve lengths.  
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Figure 5.1: Myocardial segmental division in short-axis view. Segment 17 (Cerqueira, 2002), i.e., 
myocardial apex, was omitted due to excluded long axis views.  
 
5.3.4 Image analysis 
Pre- and post-gadolinium T1 along with T2 relaxation times means were evaluated at each segment 
using respective myocardial contours. The T1 maps were generated using phase sensitive inversion 
recovery (PSIR) fitting using a three parameter signal model with motion correction [193]. Pixel-
wise myocardial T2-maps were generated using unsupervised curve-fitting based on a two-
parameter equation with motion correction [169]. Resulting T1 and T2 relaxation times were 
displayed using a bullseye plot that illustrate T1 and T2 relaxation times mean for each myocardial 
segment [195]. The threshold used to extract myocardial signal was set at: [950-1400ms] for pre-
gadolinium T1, [450-900ms] for post-gadolinium T1 and [30-60ms] for T2 relaxation times, based 
on our visual analysis of myocardial tissue relatively to adjacent tissues and in order to exclude 
adjacent tissue’s signal. We also evaluated the partition coefficient (λ) [196] of gadolinium as 
being:  
 
𝜆 =
1
𝑇1𝑃𝑜𝑠𝑡 𝑀
−
1
𝑇1𝑃𝑟𝑒 𝑀
1
𝑇1𝑃𝑜𝑠𝑡 𝐵
−
1
𝑇1𝑃𝑟𝑒 𝐵
                                                                  (5.1) 
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Where Post = post-contrast, Pre = pre-contrast, M = myocardium and B = blood. An example of 
SR and HR maps in short-axis in a standard risk vs. high risk patient is shown in figure 5.2. 
 
Figure 5.2: Myocardial T1 and T2 mapping at the mid-ventricular level of a standard risk vs. high 
risk patient. A: pre-gadolinium T1 maps (ms). B: post-gadolinium T1 maps (ms). C: T2 maps (ms). 
 
5.3.5 Statistical analysis 
Statistical comparison was done using a 1-way analysis of variance (ANOVA) on the mean 
relaxation times for each myocardial segment to compare the different groups of volunteers. A 1-
way analysis of variance on pixels, i.e., including all pixels for each segment, was also done to 
compare the different groups. When normality or equal variance tests failed, a 1-way Kruskal-
Wallis ANOVA on ranks was done. 
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Agglomerative hierarchical clustering (AHA) was also performed to verify if the different groups 
of volunteers (SR, HR and HV) could be retrieved from the MRI relaxation times. Each observation 
was considered as an initial cluster and the process successively merged clusters into larger clusters 
until it reached one big cluster containing all the samples. We used the Euclidian distance to 
determine a pairwise distance metric between each observation. The merging of clusters, or 
linkage, was based on the calculation of the Ward’s distance between clusters. The successive 
clustering operations produced a binary clustering tree (dendrogram), whose roots contained all the 
observations. 
Linear regressions were performed between T1 or T2 relaxation times and patients’ age, weight, 
height, time between end of treatment and MRI acquisition and received doxorubicin dose.  
All statistics were done using Microsoft Excel 2016 (Microsoft Corp, Redmond, WA, USA), 
except for the ANOVA that was done using SigmaPlot 12.0 (Systat Software Inc., San Jose, CA, 
USA) and the clustering which was done using XLSTATS software (Addinsoft, New York, USA). 
5.4 Results 
5.4.1 Bullseye analysis of mean T1 and T2 relaxation times 
Small differences can be seen in pre-gadolinium T1 between SR and HR groups or between HR 
and healthy volunteers, especially near myocardial free wall (Figure 5.3). Post-gadolinium T1 was 
lower in the HR group compared to the SR group. Partition coefficient of gadolinium was higher 
in the SR and HR groups compared to the healthy volunteers group (p<0.001). These differences 
were distributed over the whole myocardial area rather than within specific myocardial segments. 
The same tendency was seen for T2. HR group had higher T2 as compared to SR group with 
segment 4 being the most affected by the differences. 
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Figure 5.3: Myocardial segmental T1 and T2 relaxation times in ALL survivors (SR and HR 
groups) and healthy volunteers (HV). 
 
5.4.2 ANOVAs between HR, SR and HV 
Partition coefficient mean was 0.48 ± 0.01, 0.49 ± 0.01 and 0.38 ± 0.01 for SR, HR and HV 
respectively. Partition coefficient was significantly elevated in HR group compared to HV group 
(p<0.001) and in SR group compared to HV group (p<0.001). However, there were no significant 
differences between SR and HR groups (p=0.42). Furthermore, we found that 19 and 19 out of 19 
segments presented higher partition coefficient in HR and SR groups compared to HV group, 
respectively. Though, there were no differences between SR group and HR group when comparing 
them segment by segment. 
On the mean values per segment, pre-gadolinium T1 showed no significant differences between 
SR, HR and HV groups (p = 0.69). However, post-gadolinium T1 was significantly lower in the 
HR group compared to SR group. This finding was seen in 18 out of 19 myocardial segments. On 
the other hand, T2 relaxation times were significantly higher in HR group compared to SR group 
in 4 out of 19 segments, predominantly at apical level. Segment 8 (p=0.04), segment 14 (p=0.04), 
segment 15 (p=0.002) and segment 16 (p=0.048) were the most affected by these differences. 
On the pixels’ data, pre-gadolinium T1 was significantly lower in SR group in 8 out of 19 segments 
compared to HR group (p < 0.01). 5 out of 19 segments were significantly higher in SR group 
compared to HV group (p < 0.005) and 7 out of 19 segments were significantly higher in HR group 
compared to HV group (p < 0.005). Post-gadolinium T1 relaxation times were significantly lower 
in HR group compared to SR group in all myocardial segments (p < 0.001). T2 relaxation times 
were significantly higher in the HR group compared to the SR group in all myocardial segments (p 
< 0.001). 
Within the high risk group, patients who received dexrazoxane had slightly higher but not 
significant post-gadolinium T1 relaxation times compared to patients who did not receive 
dexrazoxane in their treatment (627 ± 47 ms vs. 589 ± 30 ms, p=0.06). However, both pre-
gadolinium T1 and T2 relaxation times were similar between the patients who received 
dexrazoxane  and the patients who did not receive dexrazoxane (1253 ± 29 ms vs. 1246 ± 17 ms, 
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p=0.51 and 45 ± 3 ms vs. 44 ± 2 ms, p=0.55, respectively). Based on doxorubicin doses alone 
(<250 mg/m2 vs. >250 mg/m2), both T1 and T2 relaxation times failed to detect significant 
differences. 
Segmental division of the myocardium revealed significant differences in pre- and post-gadolinium 
T1 between male and female patients. Within the left ventricle, pre-gadolinium T1 was 
significantly lower in male patients compared to female patients (1238 ± 20 ms vs. 1260 ± 18 ms, 
p=0.003) while post-gadolinium T1 was significantly higher in male patients compared to female 
patients (648 ± 55 ms vs. 606 ± 39 ms, p=0.02). Significant differences between the two genders 
were seen in 7 out of 19 segments for pre-gadolinium T1 and 16 out of 19 segments for post-
gadolinium T1. T2 relaxation times though, remained similar between the two groups (44 ± 3 ms 
vs. 44 ± 2 ms, p=0.74).  
5.4.3 Agglomerative hierarchical clustering analysis 
Agglomerative hierarchical clustering on the different groups of volunteers showed three main 
distinct clusters (Figure 5.4). For pre-gadolinium T1, the 3 clusters contained mixed data from the 
3 groups. However post-gadolinium T1 showed that the data from the HR and SR groups were 
included in 3 different clusters respectively. Segments 1, 3, 6, 8, 11, 14-16 were the most 
susceptible to dissociate each group in a separated cluster. For T2, the first cluster contained most 
of SR patients with an accuracy of 0.6 and a Matthews correlation coefficient (MCC) of 0.3. 
Segments 8 and 15 were the most susceptible to dissociate SR group in a separated cluster. A 
further analysis of the clusters on pre- and post-gadolinium T1 showed that the data of the HR 
patients who received dexrazoxane were included in a different cluster than the data of the HR 
patients who did not receive dexrazoxane in their treatment. 
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Figure 5.4: Hierarchical clustering analysis of T1 and T2 relaxation times. Legend: SR: standard 
risk group, HR: high risk group, HV: healthy volunteers group. 
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5.4.4 Linear regressions 
Linear regressions between relaxation times and patients’ age, weight, height, time between end of 
treatment and MRI acquisition and received doxorubicin dose showed no significant relationships. 
R-squared coefficients were equal or less than 0.25. 
5.5 Discussion 
The first aim of this study was to propose a contour-based estimation of T1 and T2 relaxation times 
based on the whole myocardial area. A robust method using skeleton-based segmentation was 
developed. Its advantages over the existing methods are that it allows both global and local analysis 
of the myocardium. Segmental division of the myocardium is completely automated and 
myocardial analysis is done in a very fast and simplified manner. The second aim was to evaluate 
T1 pre- and post-gadolinium enhancement and T2 relaxation times sensitivity to detect myocardial 
changes induced by doxorubicin-based chemotherapy in childhood ALL survivors. Local 
myocardial differences were found in pre-gadolinium T1 between SR and HR group and between 
ALL survivors and healthy volunteers. These differences were further amplified by post-
gadolinium enhancement when comparing SR group to HR group. Partition coefficient of 
gadolinium confirmed the presence of a subnormal perfusion function in ALL survivors. T2 was 
slightly higher in the high risk group than in the standard risk group. Moreover, agglomerative 
hierarchical clustering revealed clear distinction between high risk and standard risk ALL survivors 
when comparing their respective post-gadolinium T1. 
Our contour-based technique may better estimate relaxation times compared to methods based on 
regions of interests (ROIs) as it takes the whole myocardial area into account. Automatic segmental 
division of the myocardium often requires the exclusion of the right ventricle [191]. However, our 
technique includes both the left and right ventricle as myocardial skeleton is automatically 
extracted from endocardial and epicardial contour curves of the whole myocardium, and used to 
subdivide the myocardium into segments, including the right ventricle. 
Relaxation times at 3T in ALL survivors (base: 1247/44ms, middle: 1243/44ms, apex: 1261/45ms) 
were respectively slightly higher for T1 pre-gadolinium and similar for T2 relaxation times as 
compared with reported data in the literature [197] (base: 1157/44ms, middle: 1159/45ms, apex: 
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1181/47ms). However, our values of relaxation times are superior as they are obtained 
automatically and evaluated in each myocardial segment using the standard AHA segment model.  
The fact that ALL survivors, especially the HR group, had slightly higher pre-gadolinium T1 
relaxation times compared to healthy volunteers may suggest reduced systolic function [198], 
oedema or protein deposition, but not lipid or iron deposition (associated to low T1 values) [199]. 
It is known that a decrease in post-gadolinium T1 relaxation times is related to myocardial diffuse 
fibrosis [166, 165] or fibrosis scar [200, 201] due to the retention of gadolinium contrast in fibrotic 
tissue that causes T1 shortening. In our cohort of ALL survivors, post-gadolinium T1 relaxation 
times were significantly lower in HR group compared to SR group in 18 out of 19 myocardial 
segments. On the other hand, partition coefficient, which was significantly elevated in ALL 
survivors compared to healthy volunteers may suggest the presence of a reduced perfusion 
function. It was shown before that in acutely infarcted myocardium, gadolinium had a higher 
partition coefficient [196]. The partition coefficient of gadolinium determines the fibrosis index 
[202]. The constant T2 between groups suggested no infarcted myocardium [169], no acute 
ischaemic or non-ischaemic injury due to associated changes in myocardial free water content 
[203-209]. 
Agglomerative hierarchical clustering revealed clear distinction between the different groups of 
volunteers when comparing their respective post-gadolinium T1. Some segments were more 
susceptible to distinguish the different groups from each other, particularly near the apical region 
of the heart. Clustering is a powerful technique to show the sensitivity of a parameter by separating 
potential groups based on this parameter. In our study, the inclusion of dexrazoxane in the treatment 
affected the clustering of the HR group, suggesting that combined doxorubicine and dexrazoxane 
treatment induce different cardiac changes than doxorubicine alone. Dexrazoxane act as a 
cardioprotective agent by reducing free radicals formation and is associated with significant 
reduction in the incidence of myocardial injury due to doxorubicin [210, 121]. In a study comparing 
the effect of doxorubicin alone and doxorubicin with dexrazoxane, it has been shown that 
dexrazoxane has the ability to reduce free radicals formation which reduces cardiomyocyte death 
but also the reduction of myocardial stress and inflammation [211].  
In our cohort of ALL survivors, we believe that the use of dexrazoxane in their treatment may have 
significantly inhibited the apparition of further doxorubicin-induced cardiotoxicitiy. 
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The absence of differences on the relaxation times between patients who received a doxorubicine 
dose <250mg/m2 and patients who received a doxorubicine dose >250mg/m2 might be explained 
by overall moderate doxorubicin doses ranging between 59mg/m2 and 334mg/m2. The risk factor 
which takes into account the cumulative doxorubicin dose received during treatment, age at the 
beginning of the treatment and other clinical factors may be a better parameter than doxorubicin 
dose alone in distinguishing the severity of doxorubicin-induced cardiotoxicity, especially as it is 
multivariate and include the several factors that are reported to have significant risk to increase 
cardiotoxicity [212]. 
The result that female patients had higher pre-gadolinium T1 than male patients while post-
gadolinium T1 was lower in female patients compared to male patients is in agreement with 
previously reported findings [191, 213, 214]. Based on these findings, the fact that 7 out of the 9 
healthy volunteers included in this study were males may have pushed their pre-gadolinium T1 
lower while post-gadolinium T1 higher. 
The following limitations were encountered during this study. Both wall and segmental division of 
the myocardium were completely automated, however due to geometrical variations, images had 
to be normalized in terms of orientation and rotation in order to allow automation. Moreover, 
skeleton curves had to be slightly smoothed using kriging interpolator [215] due to pixelation 
effects when extracting such curves from a binary mask. Computation took less than a second to 
process each image, nevertheless it is important to mention that segmentation phase took an 
average of 3 minutes per patient, which include 3 short-axis images. 
Depending on adjacent tissue’s signal, contour-based estimation of T1 and T2 may overestimate 
or underestimate relaxation times within a given myocardial segment as it includes the whole 
myocardial wall. Some neighboring pixels may be unwantedly included while some myocardial 
pixels may be unwantedly excluded when extracting myocardial masks. However, with a 
comprehensive threshold this phenomenon of inclusion of noise pixels and exclusion of good pixels 
may be reduced to a negligible level. Right ventricular area was also assessed in this study. 
However, difficulties were encountered when delineating right ventricular walls as it is thinner than 
other regions and myocardial T1 relaxation times gets more difficult to distinguish from signal of 
the blood and adjacent tissues. Thus, right ventricular wall might be more prone to noise inclusion 
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and segmentation errors than septal or left ventricular walls. Both T1 and T2 maps were mostly 
noise-free within left ventricular and septal areas. Some T2 images had slight noise predominantly 
within the right ventricular area. To limit noise and adjacent tissue inclusion, we applied a 
comprehensive threshold. Lastly, we did not present post-gadolinium T1 comparison between the 
different groups because our cohort of ALL survivors received Gadovist as a contrast agent, 
whereas our healthy volunteers received MultiHance as a contrast agent. For this reason, we choose 
the partition coefficient, which should be insensitive to contrast agents variation, but also post 
contrast acquisition time. 
5.6 Conclusion 
Local myocardial changes were found between high risk and standard risk groups in terms of T2 
and pre- and post-gadolinium T1 relaxation times. The partition coefficient confirmed the presence 
of an abnormal perfusion function in ALL survivors. The use of T1 and T2 relaxation times, 
particularly the partition coefficient, as early indices for myocardial tissue damages in the onset of 
doxorubicin-induced cardiotoxicity should be investigated with a larger cohort of cancer survivors 
to further assess its clinical value. 
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6.1 Abstract 
Background: Displacement patterns analysis of the myocardium allows direct quantification of 
ventricular function, both locally and globally. In the presence of myocardial damage such as 
dilated cardiomyopathy, the architecture of myocardial fibers becomes abnormally stressed and 
resulting patterns of displacement change. Currently, very few techniques are available for tracking 
myocardial displacement and most of them look into ventricular function rather than displacement 
patterns. In this context, the aim of the current study was to estimate the effect of doxorubicin 
exposure during treatment for acute lymphoblastic leukemia (ALL) on 2D myocardial 
displacement patterns using cine-CMR. 
Methods: Twenty-six ALL survivors who were previously exposed to Doxorubicin and 6 healthy 
volunteers were prospectively included in this study. Cine images were acquired using an ECG-
gated cine sequence in 2-chamber, 4-chamber and short-axis views using 25 phases per cardiac 
cycle. In a first step, the myocardium was segmented using a custom-written MatLab program 
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where myocardial contours were extracted and parameterized using per-length normalization. In a 
second step, the myocardial skeleton was extracted and tracked during each phase. Finally, 
myocardial displacement along with functional indices were estimated and compared between ALL 
survivors and healthy volunteers.  
Results: Patterns of displacement were similar between ALL survivors and healthy volunteers. 
However, cumulated displacements through systolic contraction were significantly reduced in 
cancer survivors compared to healthy volunteers (p<0.001). Moreover, these differences were 
further amplified through the rest of the cardiac cycle. Healthy volunteers had more area and length 
changes compared to cancer survivors (p<0.001), especially during systolic contraction. Likewise, 
wall thickness evolution through the cardiac cycle was lesser in ALL survivors compared to healthy 
volunteers (p<0.001). Thickening fraction remained similar between ALL survivors and healthy 
volunteers in all planes. Ejection fraction was significantly reduced in ALL survivors compared to 
healthy volunteers (p<0.001) when estimating it using 2-chambers and 4-chambers view. While 
most of ALL survivors had a stable clockwise and counter-clockwise twist, the overall normalized 
rotation was slightly desynchronized with the cardiac cycle, and less than in healthy volunteers 
(p=0.02). 
Conclusion: Skeleton-based myocardial analysis provides new insights on local and global 
myocardial displacement patterns. The technique is less sensitive to tracking errors as resulting 
skeleton displacements are more stable than contour-based displacements and most importantly 
make the analysis of ventricular function easier. Displacement is significantly reduced in cancer 
survivors compared to healthy subjects, although the signature of displacement curves remains 
similar. Skeleton-based myocardial tracking may pave the way for three-dimensional tracking of 
the myocardium. 
6.1.1 Keywords 
Cardiovascular cine-MRI, myocardial tracking, myocardial displacement patterns, doxorubicin-
induced cardiotoxicity, chemotherapy 
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6.2 Background 
Doxorubicin chemotherapy is effective and widely used to treat acute lymphoblastic leukemia. 
However, its effectiveness is hindered by a wide spectrum of dose-dependent cardiotoxicity, 
including both morphological and functional changes affecting the myocardium. These changes 
include reduced left ventricular (LV) fractional shortening [121], ventricular dilatation [4], 
myocardial wall thinning [7], reduced ventricular contractile function along with radial strain 
decrease [4, 35]. Most of doxorubicin-induced myocardial damage is dose-dependant and may be 
progressive over time [121, 216], particularly in children who seem more susceptible to the 
cardiotoxic effects of doxorubicin [31]. Thus the need to detect myocardial damage early is crucial, 
especially in children where delayed cardiotoxicity may manifest years or decades later [79, 217]. 
Myocardial displacement patterns allow direct quantification of the cardiac function both locally 
and globally [218]. These displacement patterns are often investigated by using Doppler tissue 
imaging or echocardiographic speckle tracking [35, 219, 220]. In the presence of myocardial 
damage such as dilated cardiomyopathy, the architecture of myocardial fibers undergoes abnormal 
stress and displacement patterns change. In healthy hearts, these patterns provide a unique signature 
describing the resulting myocardial displacements seen on images [221]. Furthermore, tracking 
myocardial displacements is a challenging task since myocardial tissue displacement is three 
dimensional and geometrically inhomogeneous. Moreover, the accuracy of many advanced post-
processing analysis techniques such as Doppler- or speckle-derived displacements relies mainly on 
accurate myocardial tracking.  
Currently, very few techniques are available for tracking myocardial displacements in a closed-
loop cardiac cycle to assess functional abnormalities. Several MRI sequences and models were 
proposed to track myocardial displacements including the use of phase-based strain imaging 
sequences such as HARP [222] and cine DENSE [223-225, 154, 226], tagging-based sequences 
[227] and others [228, 229, 63, 65]. While most of these techniques are limited by noise and spatial 
resolution, the main limiting factors remain long acquisition times, reduced accuracy in estimating 
displacements and most importantly segmentation stage which is most of the time error prone.  
Contour-based models using cine CMR images have the potential to accurately extract myocardial 
displacements during the whole cardiac cycle [230-232], especially since cine MRI provides high 
quality cardiovascular images. Traditionally, myocardial displacements are obtained from 
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contours, segmented automatically or semi-automatically [233], either with or without anatomical 
reference points [234, 235]. Automated segmentation techniques include the deformable 
registration method, where the segmentation is based on an inverse consistent deformable 
registration approach [236]. Another fully automated segmentation technique includes the layered 
spatio-temporal forests algorithm, where the tracking is based on automatic machine learning to 
extract myocardial contours [237]. Semi-automated techniques include the contour-constrained 
optical flow tracking, where an optical flow algorithm is used to track, through the whole cardiac 
cycle, an initial contour manually drawn [238]. This technique is similar to the elastic registration 
technique, where the myocardial deformation field is parametrized using smooth basis functions, 
often B-splines in image processing, and used to track myocardial contours [239]. Another semi-
automated technique include the block matching algorithm, where epicardial and endocardial 
contours are initially drawn on the first timeframe and subsequently tracked by using the 
blockmatching technique [240, 241]. Finally, another algorithm worth mentioning is the manually 
guide-point modeling, where a small number of guide points are placed interactively on a sparse 
subset of slices and frame and tracked through the whole cardiac cycle [242].   
In general, only a few methods exploit the information provided by cardiac motion, partly because 
of the complexity and the variability of the motion model, but also because end-diastolic and end-
systolic images are sufficient for estimating the cardiac function at a clinical level [232]. The use 
of 3D models, reconstructed from cardiovascular images, to track myocardial displacements in an 
automated manner is also worth mentioning [63, 243, 159]. The use of 3D modeling has the 
advantage of providing complex and sophisticated information in terms of myocardial motion. 
However, these models are often time consuming and error prone when it comes to 3D 
reconstruction and simulation [244]. In this context, the aim of the current study was to estimate 
the effect of doxorubicin exposure during treatment for acute lymphoblastic leukemia (ALL) on 
2D myocardial displacement patterns using cine-CMR. We hypothesized that 2D displacement 
patterns within the middle slice of the myocardium can be accurately estimated from contour 
tracking and allow the detection cardiotoxic myocardial damage. 
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6.3 Method 
6.3.1 Cohort of survivors  
The present study is part of the PETALE project which is an ongoing prospective study being 
conducted at the Sainte-Justine University Hospital Center (UHC) in Montreal, Canada. The 
PETALE project addresses late chronic side effects in a cohort of Acute Lymphoblastic Leukemia  
survivors (QcALL) [192]. The main objective of PETALE is to identify genetic and biological 
biomarkers predicting long-term treatment-related health problems developments. Patients were 
recruited from the QcALL cohort after the study was approved by the institutional Review Board 
(IRB). We prospectively included 26 ALL survivors which have previously been exposed to 
Doxorubicin as a part of their chemotherapy protocol and 6 healthy volunteers. Within the ALL 
survivor group, eight (n=8) were included in the standard risk (SR) group and eighteen (n=18) were 
included in the high risk (HR) group, based on a risk index related to the severity of the pathology, 
cumulative doxorubicin dose and volunteer’s age [245, 246]. Median cumulative dose of 
Doxorubicin was 60.5 mg/m2 for SR and 286 mg/m2 for HR. 10 patients also received Dexraxozane 
as a cardioprotective agent. 13 survivors were male and 13 were females with an average at-
acquisition weight and height of 1.66 ± 0.13m and 71.3 ± 13.8kg, respectively.  Median age at ALL 
diagnosis was 24.1 ± 9.0 years. MRI scans were performed 13.6 ± 7.3 years after treatment.  
6.3.2 Cine-CMR acquisition  
Cine-CMR were acquired using a standard, ECG-gated cine sequence (Steady State Free 
Precession/SSFP) on a clinical 3T MRI system (Skyra™, Siemens Healthcare, Erlangen, Germany) 
and an 18-channel phased array body matrix coil. Acquisition parameters were: Slice thickness 
8mm, repetition time 34.6ms, effective echo time 1.2ms, flip angle 38°, iPAT factor 3, matrix 
208×210 and in-plane pixel size 1.25×1.25mm. Approximately 14 slices were acquired in a short 
axis view and 2 slices in a long axis view (2-chamber and 4-chamber). For each slice, 25 phases of 
the cardiac cycle were acquired during multiple breath-holds. The overall acquisition time 
including the 3-plane localizer scan was approximately 15 minutes. 
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6.3.3 Myocardial segmentation and displacement tracking 
Myocardial contours were semi-automatically segmented from the cine-CMR images (Figure 6.1) 
using an interactive implementation of cubic Bezier curves. We segmented one slice in 2-chamber, 
one slice in 4-chamber and one slice in short-axis view at the mid ventricular level. Once the first 
phase was segmented, at each of the following phases, a contour template based on the previous 
phase was proposed where the user needed only to correct contours relatively to the previous phase 
to limit intra-user errors. Resulting curves were re-parameterized using “cumulative percentage 
length” discretization and smoothed using geometrical kriging [215]. Myocardial displacements 
were also slightly smoothed temporarily to refine myocardial displacements through the cardiac 
cycle, but without altering the accuracy of segmentation. Furthermore, myocardial displacements 
were estimated using a skeleton-based approach. From a binary myocardial mask, a skeleton 
algorithm [194] was used to extract skeleton curves along with ending and junction points. Finally, 
skeleton curves along with end- and junction-points were further processed to compute 
perpendicular projections into myocardial contours (Figure 6.1-C).  
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Figure 6.1: Cine-CMR images in 2-chamber (left), 4-chamber (middle) and short-axis (right) views 
(A) and the resulting segmentations: contour-based (B) and skeleton-based (C). 
 
6.3.4 Contours extraction repeatability study 
For the inter-observator repeatability study, 5 experimented operators segmented myocardial 
contours on same 2-chamber, 4-chamber and short-axis cine-CMR images of the heart. The 
following workflow was implemented: 1) Segmentation of myocardial contours through the 
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creation of a closed Bezier curve, 2) excluding the papillary muscle, 3) Exclusion of atrial 
structures and 4) Other technical software-related tasks such as location and direction of contour 
initiation.  
For the intra-observator repeatability study, the same cine image was evaluated in a blinded fashion 
10 times by the same operator and using the same workflow. 
Once contours were obtained, the repeatability was evaluated using a standard deviation-based 
estimation model (Equation 6.1). 
 
𝑟𝑒𝑝𝑒𝑎𝑡𝑎𝑏𝑖𝑙𝑖𝑡𝑦 (%) ≈ 100 −
100 𝑥 𝑆𝑡𝑎𝑛𝑑𝑎𝑟𝑑_𝑑𝑒𝑣𝑖𝑎𝑡𝑖𝑜𝑛(𝑖𝑛𝑑𝑒𝑥)
𝑚𝑒𝑎𝑛(𝑖𝑛𝑑𝑒𝑥)
   (6.1) 
 
Where 𝑖𝑛𝑑𝑒𝑥 represents either the resulting area or thickness estimation from one segmentation to 
another. 
6.3.5 Displacements patterns analysis 
Myocardial displacement curves were obtained as follow: Once myocardial contours were 
calibrated using perpendicular projections of skeleton curves, contours were unfolded into 1D and 
parametrized (Figure 6.2) using the percentage of cumulative length. From the first phase of the 
cardiac cycle and at each of the following phases, absolute displacement at each point along 
myocardial contours was added cumulatively. Resulting unfolded 1D displacements were 
evaluated at three times of the cardiac cycle: at the end of systole (1-TS), at the beginning of early 
diastole (1-TDP) and at the end of the cardiac cycle (1-END), which takes into account the total 
absolute displacement during the whole cardiac cycle. An example of myocardial displacement 
paths is shown in figure 6.3. 
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Figure 6.2: Myocardial skeleton-based characteristics in 2-chamber, 4-chamber and short-axis 
views. The starting point, middle point (50% of the curve) and the end point of the myocardial 
contours are shown. 
 
 
Figure 6.3: Myocardial displacement paths in 2-chamber (A), 4-chamber (B) and short-axis (C) 
views. 
 
6.3.6 Myocardial characteristics during the cardiac cycle 
Normalized ventricular area, myocardial wall thickness and endocardial contour lengths were also 
automatically assessed, using myocardial contours in 2-chamber, 4-chamber and short-axis view. 
In order to normalize the data, each myocardial characteristic was divided by the maximum value 
reached during the whole cardiac cycle. The evolution of normalized myocardial area along with 
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the mean of myocardial wall thickness and endocardial contours length were shown during the 
whole cardiac cycle.  
6.3.7 Functional indices 
Four functional indices were automatically estimated from myocardial contours and skeleton 
characteristics: ejection fraction (EF) ratio, diastolic fraction (DF) ratio, thickening fraction (TF) 
and LV rotation angle. Conventional ejection fraction ratio was calculated using endocardial curves 
of both, left and right ventricle (Equation 6.2). In 2-chamber and 4-chamber view, caps were added 
at atrioventricular junctions to close endocardial curve in order to estimate respective ventricular 
area (Figure 6.3). 
 
𝐸𝐹 (%)  =  
𝐸𝑛𝑑 𝑑𝑖𝑎𝑠𝑡𝑜𝑙𝑖𝑐 𝑎𝑟𝑒𝑎 – 𝐸𝑛𝑑 𝑠𝑦𝑠𝑡𝑜𝑙𝑖𝑐 𝑎𝑟𝑒𝑎
𝐸𝑛𝑑 𝑑𝑖𝑎𝑠𝑡𝑜𝑙𝑖𝑐 𝑎𝑟𝑒𝑎
   (6.2) 
 
We also used the definition of the diastolic fraction ratio proposed by Okayama et al. [247] 
(Equation 6.3) and based on 30% diastolic return. 
 
𝐷𝐹 (%) =  
𝐴𝑟𝑒𝑎 𝑎𝑡 30% 𝑑𝑖𝑎𝑠𝑡𝑜𝑙𝑒 – 𝐸𝑛𝑑 𝑠𝑦𝑠𝑡𝑜𝑙𝑖𝑐 𝑎𝑟𝑒𝑎
𝐸𝑛𝑑 𝑑𝑖𝑎𝑠𝑡𝑜𝑙𝑖𝑐 𝑎𝑟𝑒𝑎− 𝐸𝑛𝑑 𝑠𝑦𝑠𝑡𝑜𝑙𝑒 𝑎𝑟𝑒𝑎
       (6.3) 
 
The thickening fraction (Equation 6.4) was based on the mean thickness of myocardial wall. 
 
𝑇𝐹 (%)  =  
𝐸𝑛𝑑 𝑑𝑖𝑎𝑠𝑡𝑜𝑙𝑖𝑐 𝑤𝑎𝑙𝑙 𝑡ℎ𝑖𝑐𝑘𝑛𝑒𝑠𝑠 – 𝐸𝑛𝑑 𝑠𝑦𝑠𝑡𝑜𝑙𝑖𝑐 𝑤𝑎𝑙𝑙 𝑡ℎ𝑖𝑐𝑘𝑛𝑒𝑠𝑠
𝐸𝑛𝑑 𝑑𝑖𝑎𝑠𝑡𝑜𝑙𝑖𝑐 𝑤𝑎𝑙𝑙 𝑡ℎ𝑖𝑐𝑘𝑛𝑒𝑠𝑠
       (6.4) 
 
Finally, to estimate LV rotation angle at the mid-ventricular level, the angle formed by the right 
ventricular insertion points in short-axis view (Figure 6.4) was followed during the whole cardiac 
cycle. Then, the maximal rotation angle through the cardiac cycle was further estimated in a global 
coordinate system.  
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Figure 6.4: LV rotation angles measurement using short-axis junction points of the skeleton at mid-
ventricular level. 
 
6.3.8 Statistical analyses  
In order to compare displacement patterns between SR and HR group and healthy volunteers, a 
Friedman repeated measures analysis of variance (ANOVA) on ranks was done on each 
displacement curve mean including 1-TS, 1-TDP and 1-END curves. However, to compare 
myocardial characteristics including myocardial area, endocardial contours length and wall 
thickness curves, a Kruskal-Wallis one-way ANOVA on ranks was done. 
Functional indices were compared using a one-way analysis of variance. Similarly, when normality 
or equal variance tests failed, an analysis of variance on ranks using Kruskal-Wallis index was 
applied. 
6.4 Results 
6.4.1 Repeatability study 
Intra-observer repeatability for myocardial area estimation was 97.3% and 96.3% for LV and RV 
contours, respectively. Thickness estimation repeatability was 96.2%, 96.7% and 97.3% for LV, 
SE and RV contours, respectively. In terms of contours position, the mean intra-observer position 
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error was 0.46mm, 0.43mm and 0.46mm from endocardial LV, endocardial RV and epicardial 
curve positions. Variations were higher at first image and tended to decrease through the cardiac 
cycle.  
 
Inter-observer repeatability for myocardial area estimation was 77.9% and 91.9% for LV and RV 
contours, respectively. Extra-observator repeatability for thickness estimation was 80.5%, 83.2% 
and 73.3% for LV, SE and RV contours, respectively. The mean inter-observer position error was 
1.85mm, 1.32mm and 1.04mm from endocardial LV, endocardial RV and epicardial curve 
positions. Again, variations were small at first image and tended to increase through the cardiac 
cycle. 
6.4.2 Displacement patterns 
Patterns of displacement were similar between cancer survivors and healthy volunteers (Figure 
6.5). Cumulated displacements through systolic contraction, i.e., phase 1 to end-diastole (1-END) 
were significantly reduced in cancer survivors compared to healthy volunteers in all planes 
(p<0.001). Moreover, these differences were further amplified through the rest of the cardiac cycle.  
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Figure 6.5: Myocardial displacement patterns generated during the whole cardiac cycle in 2-
chamber, 4-chamber and short-axis (SA) views. Each curve represents unfolded contour 
displacement through the whole cardiac cycle. 
 
6.4.3 Myocardial characteristics during the cardiac cycle 
When looking into normalized LV area changes through the cardiac cycle in a 2-chamber view 
(Figure 6.6), healthy volunteers tended to have larger area changes compared to cancer survivors 
(p<0.001), especially during systolic contraction. This finding was further confirmed when 
comparing endocardial contour length evolution through the cardiac cycle. Likewise, myocardial 
contractile function, i.e. wall thickening, was reduced in cancer survivors compared to healthy 
volunteers (p<0.001). The same finding was seen in 4-chamber view (Figure 6.7). However, in 
short axis views (Figure 6.8), the differences in terms of ventricular area and endocardial contours 
length were smaller. On the other hand, the same findings were seen using right ventricular area, 
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length and wall thickness in a 4-chamber view. In short axis planes however, no differences were 
seen either between SR and HR or between the cohort of ALL survivors and healthy volunteers.  
  
Figure 6.6: Normalized myocardial characteristics in 2-chamber view. 
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Figure 6.7: Normalized myocardial characteristics in 4-chamber view. 
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Figure 6.8: Normalized myocardial characteristics in short-axis view. 
6.4.4 Functional indices 
Thickening fraction remained similar between ALL survivors and healthy volunteers in all planes 
(Figure 6.9). LV ejection fraction was significantly reduced in ALL survivors compared to healthy 
volunteers when estimating it using 2-chamber (42±4% vs 53±6%, p<0.001) or 4-chamber (43±5% 
vs 50±4%, p<0.001) views. However, when using conventional short axis views, the index failed 
to detect any significant differences between both SR and HR groups (43±7% vs 43±6%, p=0.37) 
or between ALL survivors and healthy volunteers (43±6% vs 47±8%, p=0.36). Based on the 
standard deviation of indices from one volunteer to another, conventional ejection fraction index 
was the most stable as compared to the other indices as it had the lowest inter-volunteers standard 
deviation. The diastolic fraction in 4-chamber view was lower in ALL survivors as compared to 
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healthy volunteers (31±13% vs 50±16%, p=0.02), but only for the right ventricle. LV diastolic 
fraction in 4-chamber view was similar between ALL survivors and healthy volunteers (36±16% 
vs 35±20%, p=0.84). Similarly, LV diastolic fraction was similar between ALL survivors and 
healthy volunteers in 2-chamber (37±20% vs 40±15%, p=0.35) and short-axis views (42±18% vs 
41±13%, p=0.44). 
 
Figure 6.9: Myocardial skeleton-based functional indices in 2-chamber, 4-chamber and short-axis 
views. TF: thickening fraction, EF: ejection fraction, DF: diastolic fraction based on 30% diastolic 
return, RV: right ventricle, LV: left ventricle. 
 
Cancer survivors had significant lower rotation angles (Figure 6.10) than healthy volunteers 
(5.7±2.5°, 8.6±4.2°, respectively, p=0.02). SR group had slightly lower rotation angle than HR 
group (4.9±1.1°, 6.1±2.9°, respectively, p=0.02). While most of ALL survivors had a stable 
clockwise and counter-clockwise twist, the overall normalized rotation seemed slightly 
unsynchronized with the cardiac cycle (Figure 6.10). 
 
75 
 
Figure 6.10: LV rotation angle distribution through the cardiac cycle. 
 
6.5 Discussion 
Parameters of myocardial displacement were found sensitive to identify abnormal function in 
patients after cardiotoxic chemotherapy. Their variation through the cardiac cycle allowed for a 
detailed analysis of functional abnormalities associated with doxorubicin therapy, more present 
during systole than during diastole. As traditional functional parameters were not significantly 
different between ALL survivors and healthy subjects, the data indicate that displacement 
parameters may be more sensitive biomarkers of doxorubicin-induced cardiotoxicity. 
6.5.1 Advantages of skeleton-based technique 
The proposed skeleton-based technique allowed for an accurate estimation of displacement patterns 
since displacements are calibrated using skeleton characteristics. Moreover, it did not require 
anatomical points to be manually selected as starting or ending points of contours. Such anatomical 
points are necessary in contour-based tracking [220] to associate contours from one phase to 
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another of the cardiac cycle. Using raw contours to track myocardial displacement, where 
displacements are obtained simply by subtracting position from one curve to another, induces 
sliding along myocardial contour curves that hampers the estimation of both, myocardial 
displacement patterns and functional indices. Even with the use of anatomical markers to 
parametrize myocardial contours, the induction of marker sliding along contours from one phase 
to another may be significant. Thus, anatomical markers were omitted during this study because of 
the difficulty finding a stable anatomical marker which can be accurately tracked through the whole 
cardiac cycle. Curvature-based tracking using raw contours to track myocardial displacement was 
also omitted for the same reasons. On the other hand, this sliding phenomenon was significantly 
reduced when using skeleton-based tracking due to the skeleton characteristics and curves that are 
relatively stable from one phase to another. The advantage of using kriging interpolator over a 
divergence-free displacement field [243, 159] is that we can smooth myocardial displacements 
when required. Smoothing is important especially when segmentation errors generate important 
noise within myocardial wall. 
6.5.2 Segmentation errors and data normalization  
All functional indices presented in this study were estimated automatically during the post-
segmentation process, thus the accuracy of post-processing parameters was mostly dependent on 
the segmentation, which was the main source of errors. Reported segmentation errors for short axis 
cine-CMR images (1 to 3 mm) are equal to slightly higher than our inter-observer repeatability, but 
higher than our intra-observer repeatability [232, 248]. Small variations between ALL survivors in 
terms of contours geometry were noted mainly in 2-chamber and 4-chamber views, however, these 
variations are induced due to CMR acquisitions, more specifically, due to three-dimension slice 
localization. As opposed to whole-cycle tracking, functional indices required segmenting two or 
three phases instead of all phases of the cardiac cycle, thus involve less image processing. 
Furthermore, most of indices and results shown in this study were normalized to limit their 
sensitivities to image acquisition parameters and allow inter-volunteers comparison. It is important 
to keep in mind that from one survivor to another, myocardial geometry may change significantly. 
Orientation and position of MR acquisition plane along with the overall volume of the heart, which 
may also vary significantly, may further confirm the need to normalize both input and output data 
to allow inter-volunteers comparison. 
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6.5.3 Myocardial displacement patterns in cancer survivors 
The similar myocardial displacement patterns between cancer survivors and healthy volunteers 
suggested that myocardial contours followed a specific signature in terms of displacements and 
this signature of displacements remained unchanged. The higher amplitude in healthy volunteers 
compared to ALL survivors along most of myocardial contours suggested that myocardial strain, 
conventionally investigated by echocardiography, may be reduced in this cohort of cancer 
survivors as it was found in an animal model [35]. Systolic dysfunction appeared with a reduction 
in both longitudinal and circumferential strain, while LV ejection fraction remained within the 
normal range in anthracycline-treated cancer survivors [249]. Radial displacement was also 
reported to be lower in anthracycline-treated cancer survivors [250]. Such parameters, used to 
quantify myocardial mechanics, may be predictors for overall mortality and major cardiac events 
following anthracycline-based treatments [250, 249]. Longitudinal strain in particular seem to have 
superior prognostic value when it comes to detecting clinical heart failure [249]. The fact that the 
same finding was seen in 2-chamber, 4-chamber and short-axis views, including both left and right 
ventricular endocardial curves, suggested that the whole 3D deformation of the heart may become 
altered due to doxorubicin-based treatment.  
6.5.4 Myocardial characteristics 
When comparing ventricular area and myocardial contour length, normalized ventricular area was 
the most stable parameter, i.e., with smallest inter-subject variations. Its similar evolution through 
the cardiac cycle between SR and HR group suggested that this parameter is insensitive to the risk 
factor. However, 10 survivors within the HR group received Dexrazoxane as a cardioprotective 
agent, which may have inhibited doxorubicin-induced cardiotoxicity and narrowed the differenced 
between SR and HR group in our cohort of patients. The differences between ALL survivors and 
healthy volunteers in 2-chamber and 4-chamber views, especially during systole, suggested that 
there is a clear reduction of cardiac output in ALL survivors. In these settings, we believe that the 
use of LV volumes may rather be more appropriate as it was previously reported that LV end-
systolic volume significantly increases in cancer survivors [251-253], which may be a sign of early 
cardiotoxicity. An increase in LV end-systolic volume should be expressed by a lower ejection 
fraction. However, measuring volumes is more stable than quantifying the two dimensional 
ventricular area since such measurement is insensitive to errors due to slice position during images 
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acquisition. Contours length on the other hand was also stable from one volunteer to another. 
However, the smaller amplitudes of contours length compared to ventricular area induced less 
susceptible differences between ALL survivors and healthy volunteers. 
6.5.5 Functional indices 
The use of anthracyclines was previously reported to induce a reduction in the LV wall-thickness 
along with thickness-dimension ratio [254]. However, in our study the LV myocardial wall 
thickening fraction remained similar between ALL survivors and healthy volunteers in all 
myocardial planes, which suggested that the contractile function of the myocardium may not be as 
affected as previously found [254]. On the other hand, the fact that the distribution of normalized 
wall thickness over the cardiac cycle was lower in ALL survivors compared to healthy volunteers 
in 2-chamber and 4-chamber but not in short-axis gives different views on such parameter.  
The LV ejection fraction was expected to be reduced [4, 8]. A significant reduction however was 
only observed when measurements were performed in 2-chamber and 4-chamber views, which 
might be due to the presence of regional myocardial tissue damage. Dietz et al. [250] reported a 
non-significant trend for a lower ejection fraction in cancer survivors. Several other studies 
however reported a significant reduction. In a report including 62 cancer survivors, subnormal LV 
ejection fraction was detected in 61% of cancer survivors while right ventricular ejection fraction 
in 53% [251]. In another study including 64 cancer survivors imaged with CMR, 49 (77%) had an 
abnormal LV ejection fraction [252]. In this study, the two methods used to calculate the ejection 
fraction, using either myocardial contour length or myocardial area, gave the same results. A 
significant reduction was seen in 2-chamber and 4-chamber views while normal values were 
obtained in conventional short axis views, which indicates subclinical changes of ventricular 
function. On the other hand, LV diastolic fraction ratio, which was expected to be reduced due to 
doxorubicin-based therapy [249], also failed to detect differences between cancer survivors and 
healthy volunteers using either 2-chamber, 4-chamber or short-axis view. Though, this index was 
less stable due to its higher standard deviation compared to other indices. Though, a further look 
at this index should be made, since it may detect abnormal myocardial diastolic function that is 
often reported in cancer survivors [255, 137, 256]. 
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6.5.6 LV rotation 
The reduction of LV rotation in cancer survivors confirm previously reported findings [257] and 
suggests a possible alteration of fiber integrity. LV rotation is a phenomenon seen in short axis 
views where the heart undergoes a rotation pattern during each cardiac cycle. LV rotation is closely 
related to both, systolic and diastolic function when acquired during the whole cardiac cycle and 
may be altered in multiple diseases such as systolic or diastolic heart failure, dilated 
cardiomyopathy, hypertrophic cardiomyopathy and constrictive pericarditis [258]. LV rotation is 
maximal during both clockwise and counter-clockwise rotation at the apex and minimal at basal 
level. Contrary to tagging MRI where tag lines tend to disappear at the end of systole contraction 
[259], thus limiting estimation accuracy, skeleton-based estimation is not sensitive to the phase of 
the cardiac cycle. The reported mean rotation angle at mid-ventricular level in healthy humans is 
3.7±0.8° at epicardium and 7.0±2.1° at endocardium [260]. However, using circumferential points 
on tagging MRI to estimate LV rotation may provide variable results due to non-uniform 
deformation of the myocardium. Moreover, rotation angles differ significantly between 
endocardial- vs. epicardial-based measurement. A further look into this index in cancer survivors 
and healthy volunteers may be required to further assess its use as a new biomarker of LV rotation 
and as a potential clinical index of myocardial contractile function. 
6.5.7 Study limitations 
Three main limitations were encountered during this study. Firstly, the through-plane motion was 
not taken into account when estimating myocardial displacements. Thus, the 2D/planar analysis of 
displacements may not provide full characterization of myocardial behaviour. However, the same 
problem arises when using echocardiography images. Secondly, the duration of the different 
cardiac intervals (early and late diastole) were relatively different from one volunteer to another, 
thus, required manual selection of each key phase of the given cardiac interval, which added one 
to two minutes to process volunteers’ data. Thirdly, this study included only 26 ALL survivors and 
6 healthy volunteers. Though, a larger cohort of volunteers may be required to further confirm our 
findings. 
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6.6 Conclusion 
Skeleton-based myocardial analysis provided new insights in terms of both local and global 
myocardial displacement patterns. The technique is less sensitive to tracking errors as resulting 
skeleton displacements are more stable than contour-based displacements and most importantly 
make the analysis of the cardiac function easier. Within the cohort of volunteers that were assessed 
in this study, displacement patterns were significantly lower in cancer survivors compared to 
healthy volunteers, although the signature of displacement curves remained similar. The use of 
skeleton-based myocardial tracking should further be considered and may open doors to a future 
three-dimensional tracking of the myocardium. 
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7.1 Abstract 
Background: Doxorubicin-based chemotherapy is an effective treatment for cancer, however its 
successes are hindered by its alterations of myocardial physiology at multiple stages. From 
molecular scale up to morphological and functional scale, the induction of multiple cardiotoxicities 
is reported. However, the heart is relatively complex to track since it has much fewer anatomical 
landmarks than other organs. The aim of this study was to develop a method based on 
cardiovascular cine-MRI and finite element modeling to evaluate 2D myocardial regional 
mechanical strain and stresses in childhood acute lymphoblastic leukemia (ALL) survivors who 
previously received doxorubicin therapy. We hypothesized that mechanical strain and stresses will 
enable the detection of any alterations to both contractile and relaxation functions of the 
myocardium.   
Methods: We prospectively included 26 ALL survivors who underwent a doxorubicin-based 
chemotherapy for childhood leukemia and 6 healthy volunteers (HV). The ALL survivors group 
was divided into a standard risk (SR) group (n=8) and a high risk (HR) group (n=18), based on the 
cumulative doxorubicin dose received during treatment, age at the beginning of the treatment and 
other clinical factors. The MRI protocol consisted of an ECG-gated cine TruFISP sequence using 
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a Siemens 3T MRI system. Myocardial contours were semi-automatically segmented on the mid-
ventricular 2-chamber, 4-chamber and short-axis images using an interactive implementation of 
cubic Bezier curves. Myocardial geometry was meshed at each phase of the cardiac cycle, and then 
deformed with myocardial displacements obtained from the calibrated contours. Strain and stresses 
were estimated using hyperplastic finite-element model and either linear or cumulative technique. 
Linear technique required only the first and last phases of the given cardiac interval while 
cumulative technique required each phase to be segmented and transitory strain and stresses 
cumulatively added through the cardiac interval. Mean strain and stresses (XY resultant or von 
Mises index) were evaluated during systole, early diastole and late diastole intervals. Statistical 
comparison between volunteers was done using a one-way analysis of variance. 
Results: Von Mises strain and stresses were higher than XY strain and stresses during systole, 
early and late diastole. Linear strain and stresses were comparable to cumulative strain during 
systole. However, during diastole, cumulative strain and stresses were higher than linear strain and 
stresses. These differences were observed within the whole myocardial area rather than specific to 
some myocardial segments. During early diastole, myocardial strain remained similar between the 
groups (p>0.1). However, during late diastole, myocardial strain were significantly reduced in SR 
and HR groups compared to healthy volunteers (p<0.004). Myocardial stresses were significantly 
reduced during early diastole in SR and HR groups compared to healthy volunteers, but only in 4-
chamber view (9.69 ± 4.91 kPa and 9.90 ± 4.51 kPa vs. 13.52 ± 6.00 kPa, respectively, p=0.04). 
During late diastole, myocardial stresses were reduced in both 2-chamber (8.55 ± 2.98 kPa and 
6.59 ± 1.50 kPa vs. 10.6 ± 3.6 kPa, p=0.004) and 4-chamber (8.05 ± 4.18 kPa and 6.69 ± 2.53 kPa 
vs. 10.2 ± 4.3 kPa, p=0.023) views. 
Conclusion: Our new skeleton-based technique provided robust results and accurate tracking of 
myocardial tissue for further quantification of apparent strain and mechanical stresses. Cumulative-
based estimation of strain and stresses allows mesh restructuration at each phase and thus, is more 
appropriate for large displacements. The apparent strain and stresses were significantly lower in 
doxorubicin-treated ALL survivors, which may indicate a reduction in myocardial contractile and 
relaxation function. Taking into account the non-linear myocardial displacements through this 
cumulative-based estimation of strain and stresses help in detecting any alterations in myocardial 
tissue properties. 
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7.1.1 Keywords 
Myocardial stresses, myocardial strain, finite-element modelling, doxorubicin-induced 
cardiomyopathies, chemotherapy, cine-CMR 
7.2 Introduction 
Doxorubicin-based chemotherapy is known as an effective treatment for cancer, however its 
successes are hindered by its alterations of myocardial physiology at multiple stages. At molecular 
scale, doxorubicin is known to induce reactive oxygen species [11, 13]. At electrophysiological 
scale, it induces premature ventricular contraction [4] and sinus tachycardia [2]. Lastly, at 
morphological and functional scale, the induction of wall thinning [7, 4] or ventricular contractile 
dysfunction [35, 4] is reported. 
The use of mechanical strain and stresses may provide useful knowledge that may help in detecting 
doxorubicin-induced damage at a functional scale. Such parameters play an important role in the 
mechanical function of the heart [261], especially during passive ventricular filling. Reported use 
of these mechanical parameters include myocardial ischemia [262], systolic dysfunction [263] and 
regional myocardial function quantification [264, 265]. Most of reported studies use 
echocardiography to estimate myocardial strain and stresses. However, the geometric assumptions 
behind echocardiography, which affect both the M mode and two dimensional (2D) 
echocardiography, may lead to inaccurate measurement of strain and stresses [47]. 
Accurate estimation of myocardial strain and stresses requires accurate tracking of myocardial 
displacements. However, the heart is relatively complex to track since it exhibits much fewer 
anatomical landmarks than other organs such as the brain [266]. The standard technique used to 
track myocardial displacements remains the tagging sequence [267, 268]. Such technique requires 
complex algorithms and a contour model to track myocardial displacements, and its accuracy 
decreases through the cardiac cycle as the tagging signal decreases due to spin-lattice relaxation of 
the tagged tissue [269]. Alternative methods used to track myocardial displacements include elastic 
registration technique, where displacements are usually obtained directly from a phase-by-phase 
registration [270-273, 239]. Another technique is the contour-based segmentation with a model-
based tracking, where the intra-myocardial displacement is interpolated from resulting contour 
displacements [274, 151]. Many of these 2D models serve as building stages for a 3-dimensional 
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model, which are more appropriate to take into account the through-plane motion for a better 
characterization of myocardial mechanical characteristics.  
Reported finite element (FE) models include a promising 2D stochastic FE framework that 
simultaneously estimates left ventricular myocardium kinematics and mechanical parameters using 
a dynamic equation accounting for mass, damping and stiffness properties [71]. This model uses a 
contour-based tracking technique [275], but does not seem to exclude trabeculae carneaes during 
segmentation process, which can generate important errors in mechanical properties estimation. A 
3D-based biventricular FE model was also proposed from interactive segmentation of cine MRI 
images and automatic reconstruction using 2D control curves [61]. The combined use of 
electrophysiological and mechanical heart models is also worth considering since they provide 
unprecedented potential to quantify myocardial alterations [61], especially in 3D analysis. Such 
models may not only allow the development of more sensitive clinical indices to detect 
cardiomyopathies [61], but also to locate regional alterations. However, although the model allows 
a direct estimation of myocardial mechanical properties, several limitations remain considerable 
including the absence of a robust parametric model. While the model does not incorporate patient-
specific fibers orientation, it can generate fibers orientation from statistical atlas information. Such 
property is necessary in detecting regional alterations of the myocardium. A complete geometric 
model including both the ventricular and atrial part was obtained from an iterative adaptation 
approach using tomographic data, with reported segmentation errors of 4.5-7mm [62]. Another 3D 
FE model can automatically generate personalised biomechanical models from 3D cardiovascular 
images [63]. Although the model is fairly complex, include fibers orientation and allow the 
simulation of both systole and diastole, it however lacks the inclusion of the right ventricle. None 
of the FE based biventricular models [67, 57, 276, 277] provided the possibility of quantifying 
local myocardial alterations, as they are not parameterized and cannot be divided into the standard 
17 segments model.  
3D FE models have the advantage to represent the complex physiological behavior of the heart.  
However, due to the lack of myocardial subdivision standard, we chose a 2D analysis of myocardial 
mechanical strains and stresses. We hypothesized that 2D mechanical strain and stresses enable the 
detection of any alterations to both contractile and relaxation functions of the myocardium. The 
aim of this study was to develop a method based on cardiovascular cine-MRI (cine-CMR) and FE 
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modeling to evaluate 2D myocardial regional mechanical strain and stresses in childhood ALL 
survivors who previously received doxorubicin therapy for leukemia. 
7.3 Methods 
7.3.1 Cohort of volunteers 
After approval by the institutional Review Board (IRB) and obtaining informed voluntary consent, 
we prospectively included 26 ALL survivors, from the PETALE study [192] and 6 healthy 
volunteers. These ALL survivors have previously undergone a doxorubicin-based chemotherapy 
for childhood leukemia. Within the ALL survivor group, eight (n=8) were included in the standard 
risk (SR) group and eighteen (n=18) were included in the high risk (HR) group, based on a risk 
index related to the severity of the pathology, cumulative doxorubicin dose and volunteer’s age 
[245, 246]. 13 ALL survivors were male and 13 were females with an average at-acquisition weight 
and height of 1.7 ± 0.1m and 71.3 ± 13.8kg, respectively. Treatment was received on an average 
of 2.0 ± 0.5 years post-diagnosis whereas MRI acquisitions were made 13.6 ± 7.3 years post-
treatment. The ALL survivors received doxorubicin doses of 241 ± 97 mg/m2 while 10 of the HR 
group received dexrazoxane doses of 2749 ± 463 mg/m2. The healthy volunteers (HV) mean age 
was 34 ± 9 year while their mean weight was 59 ± 7 kg. 
7.3.2 MRI acquisition 
The MR protocol consisted of an ECG-gated cine TruFISP sequence acquired during breath-holds, 
using a Siemens 3T MR system. Acquisition parameters were slice thickness 8 mm, repetition time 
34.5 ms, effective echo time 1.2 ms, flip angle 36°, iPAT factor 3, matrix 208 × 210 and pixel 
spacing 1.25 × 1.25 mm. Approximately 14 slices were acquired in short-axis and 5 slices in long 
axis 4-chamber and 2-chamber views. For each slice, 25 phases of the cardiac cycle were acquired 
during multiple breath-holds. The overall acquisition time including the 3-plan Localizer scan was 
approximately 15 minutes. 
7.3.3 Myocardial contours tracking 
Myocardial contours were semi-automatically segmented using an interactive implementation of 
cubic Bezier curves. Segmentation was done at the mid-ventricular level in short-axis, 2-chamber 
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and 4-chamber views. Once the first phase was segmented, at each following phases a template, 
based on the previous phase, was proposed where the user needs only to apply relative displacement 
from one phase to another to limit intra-operator errors. In short axis view, three curves were used 
to segment myocardial area: endocardial left and right ventricular curves and epicardial curve 
whereas in 2-chamber and 4-chamber views, only one curve was required to segment the whole 
myocardial area (Figure 7.1). Resulting curves were re-parameterized using “cumulative 
percentage length” discretization and smoothed using geometrical kriging [215]. Intra-myocardial 
displacements were estimated using a skeleton-based approach. From binary myocardial mask, a 
skeleton algorithm [194] was used to extract skeleton curves along with ending and junction points. 
Finally, end and junction points were further processed to compute perpendicular projections onto 
initial myocardial contours. Myocardial contours characteristics and endocardial curves directions 
are shown in Figure 7.1. 
 
Figure 7.1: Myocardial regions for strain and stresses estimation. Legend: LV: left ventricle, SE: 
septum, RV: right ventricle. Note: numbers 7 to 12 and 19 correspond to myocardial segments 
based on the standard 17-segment AHA model. 
 
7.3.4 Myocardial strain and stresses estimation 
We used an isotropic hyperplastic model with a discrete distribution of Young’s Modulus 
(Equation 7.1) estimated from published data [73], based on different strain (𝜖) intervals: 
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     𝑌𝑜𝑢𝑛𝑔 𝑀𝑜𝑑𝑢𝑙𝑢𝑠𝑖  (N/mm
2) ≈ {
0.013 ,
0.016 ,
0.064 ,
0.1 ,
     
         𝜖 = 0.00, . .  0.05
         𝜖 = 0.05, . .  0.10
         𝜖 = 0.10, . .  0.15
         𝜖 = 0.15, . . 0.20
     
 (7.1) 
 
In a first step, the cardiac cycle was divided into three main intervals which included systole, early 
diastole (ED) and late diastole (LD) (Figure 7.2). Selection of the beginning and last phase of each 
interval was done manually by selecting end-systolic and end of early diastole phases. End diastole, 
i.e., start of systole, happened to always be the first phase as the MRI acquisition was ECG gated 
with the cardiac cycle. In a second step, myocardial geometry was meshed at each phase of the 
cardiac cycle using a meshing algorithm that generates 2D unstructured triangular meshes [278]. 
In a third step, intra-myocardial displacements were injected as loading condition into the FE 
model. In a fourth step, strain and stresses were estimated using either linear or cumulative 
technique (Figure 7.2). Linear technique required only the first and last phase of the given cardiac 
interval in order to estimate strain and stresses. However, cumulative technique required each phase 
to be segmented. The initial phase was geometrically deformed using kriging interpolator to fit the 
next phase in order to estimate transitory strain and stresses. These transitory strain and stresses 
were then cumulatively added through the cardiac interval. Finally, strain and stress indices were 
displayed using either XY resultant (Equation 7.2) or von Mises index (Equation 7.3), with plane 
stress assumption in a global coordinate system. For a given phase A-to-B simulation, results are 
always shown in the final resulting phase, for consistency.  
 
𝜎𝑋𝑌 = √𝜎𝑋2 − 𝜎𝑌2     (7.2) 
𝜎𝑉𝑀 = √𝜎𝑋2 − 𝜎𝑋𝜎𝑌 + 𝜎𝑌2 + 3𝜎𝑋𝑌2    (7.3) 
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Figure 7.2: Comparison of linear and cumulative methods from stresses and strain estimation. 
 
7.3.5 Strain and stresses sensitivity to segmentation errors 
Contour repeatability and reproducibility were previously assessed. To summarize, for intra-
observator repeatability, the same cine-CMR images were given blindly 5 times to the same 
operator. The main rules included: segmentation of myocardial contours using a closed contour 
curve, exclusion of auricular myocardium, exclusion of the papillary muscle and others software-
related constraints such as where and in which direction to begin each myocardial contour curve. 
Once contours were segmented, the repeatability was evaluated in 2-chamber, 4-chamber and 
short-axis view using a standard deviation-based estimation model (Equation 7.4). 
 
89 
𝑟𝑒𝑝𝑒𝑎𝑡𝑎𝑏𝑖𝑙𝑖𝑡𝑦 (%) ≈ 100 −
100 𝑥 𝑆𝑡𝑎𝑛𝑑𝑎𝑟𝑑_𝑑𝑒𝑣𝑖𝑎𝑡𝑖𝑜𝑛(𝑖𝑛𝑑𝑒𝑥)
𝑚𝑒𝑎𝑛(𝑖𝑛𝑑𝑒𝑥)
  (7.4) 
 
Where 𝑖𝑛𝑑𝑒𝑥 represents either the resulting strain or stresses from one segmentation to another. 
For inter-observator repeatability, the same short-axis images were segmented blindly by three 
different operators using the same rules. Generated strain and stresses during systole were therefore 
used to estimate repeatability. 
7.3.6 Statistical analysis 
Statistical comparison between ALL survivors and healthy volunteers was done using a one-way 
analysis of variance (SigmaPlot 12.0, Systat Software, Inc., Point Richmond, CA). When normality 
test failed, a Kruskal-Wallis one-way analysis of variance on ranks was done. 
7.4 Results 
7.4.1 Repeatability study 
Intra-observervator repeatability for myocardial strain estimation was 87.0% and 92.0% and 91.3% 
for 2-chamber, 4-chamber and short axis, respectively. Intra-observervator repeatability for 
myocardial stresses estimation was 74.8% and 85.7% and 86.4% for 2-chamber, 4-chamber and 
short axis, respectively. Myocardial stresses were slightly less repeatable than myocardial strain. 
In terms of mean strain estimation, the standard deviation of resulting strain was 16.8%, 10.9% and 
7.4% in 2-chamber, 4-chamber and short axis, respectively. The standard deviation of resulting 
stresses was 20.4 kPa, 8.90 kPa and 4.30 kPa in 2-chamber, 4-chamber and short axis, respectively. 
Inter-observator repeatability for systolic strain and stresses estimation were 83% for strain and 
70% for stresses. The standard deviation was 42% for strain and 28.6 kPa for stresses. 
7.4.2 XY versus von Mises representation of strain and stresses. 
Von Mises strain were higher than XY strain during systole, early and late diastole (Figure 7.3). 
The same finding was seen when estimating myocardial stresses.  
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Figure 7.3: Comparison of linear von Mises and linear XY strain and stresses during diastole. 
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7.4.3 Linear versus cumulative strain and stresses 
Linear strain were comparable to cumulative strain during systole (Figure 7.4). However, during 
diastole, cumulative strain were higher than linear strain. These differences were observed within 
the whole myocardial area rather than specific to some myocardial segments. Linear strain during 
systole were slightly higher than linear strain during diastole. However, cumulative strain during 
diastole were slightly higher than cumulative strain during systole. Furthermore, both linear and 
cumulative strain were higher during early diastole than during late diastole. 
 
Figure 7.4: Comparison of linear and cumulative strain in the different myocardial segments. 
Legend: RV: right ventricle, LV: left ventricle, SE: septum, SA: short axis. 
 
Stresses, but not strain, were underestimated when using cumulative estimation technique 
compared to the linear estimation technique (Figures 7.5 and 7.6). Strain and stresses generated 
during early diastole tended to be higher compared to strain and stresses generated during late 
diastole. All these finding were seen in both ALL survivors (both HR and SR groups) and healthy 
volunteers.  
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Figure 7.5: Early diastolic loading condition, resulting displacements and resulting von-Mises 
strain and stresses for an ALL survivor.  
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Figure 7.6: Late diastolic loading condition, resulting displacements and resulting von-Mises strain 
and stresses for the same ALL survivor as in Figure 7.6.  
 
7.4.4 Volunteers groups analysis 
ALL survivors had lower cumulative strain and stresses than healthy volunteers during diastolic 
relaxation, in 2-chamber, 4-chamber and short-axis views (Figure 7.7). Myocardial strain and 
stresses were slightly higher during early diastole compared to late diastole. During systole, SR 
and HR groups had also slightly lower cumulative von Mises strain and stresses than healthy 
volunteers. 
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Figure 7.7: Cumulative von Mises strain and stresses comparison between ALL survivors and 
healthy volunteers, during early and late diastole. 
 
During early diastole, myocardial strain remained similar between the different groups of 
volunteers (2-chamber: p=0.373, 4-chamber: p=0.176 and short-axis: p=0.127). However, during 
late diastole, myocardial strain were significantly reduced in SR and HR groups compared to 
healthy volunteers (71 ± 14% and 61 ± 12% vs. 100 ± 20%, respectively, p<0.001) in 2-chamber 
view. The same finding was seen in 4-chamber (66 ± 23% and 61 ± 17% vs. 92 ± 21%, respectively, 
p=0.004) and short-axis (57 ± 22% and 51 ± 16% vs. 68 ± 17%, respectively, p=0.008) views. In 
short-axis, this reduction was seen over the whole myocardial area rather than specific to some 
segments. 
Myocardial stresses were significantly reduced during early diastole in SR and HR groups 
compared to healthy volunteers, but only in 4-chamber view (9.69 ± 4.91 kPa and 9.90 ± 4.51 kPa 
vs. 13.52 ± 6.00 kPa, respectively, p=0.038). During late diastole, myocardial stresses were reduced 
using both 2-chamber (8.55 ± 2.98 kPa and 6.59 ± 1.50 kPa vs. 10.6 ± 3.6 kPa, p=0.004) and 4-
chamber (8.05 ± 4.18 kPa and 6.69 ± 2.53 kPa vs. 10.2 ± 4.3 kPa, p=0.023) views. 
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7.5 Discussion 
The objective of this study, which was to develop a method based on cine-CMR and finite element 
modeling to evaluate 2D regional myocardial function in childhood ALL survivors, was 
successfully reached. Myocardial strain generated during late diastole were significantly reduced 
in ALL survivors compared to healthy volunteers in 4-chambers, 2-chambers and short-axis views, 
which may suggest a possible reduction in the myocardial relaxation function in ALL survivors. 
Myocardial stresses were significantly reduced in ALL survivors compared to healthy volunteers 
only in 4-chambers view. The fact that myocardial stresses remained similar between ALL 
survivors and healthy volunteers in 2-chambers and short-axis views suggests that myocardial 
changes may be local rather than generalized over the whole ventricular myocardium.  
The use of raw contours may induce a sliding phenomenon along the curves which may result in 
incorrect strain estimation, especially in terms of shear strain in regions such as the right ventricular 
wall. Displacements from elastic registration [239] may be accurately estimated if myocardial 
displacements are small enough, which is not the case for myocardial displacements. Estimating 
myocardial displacements using skeleton-based technique provided an accurate estimation since it 
was based on geometry characteristics of the myocardium. Reconstituting contours from the 
skeleton provided accurate tracking of myocardial wall without sliding phenomenon, especially in 
short-axis view. However, errors on the estimation of end-points position seem to affect 
myocardial displacement estimation only in 2-chamber and 4-chamber views contrary to short-
axis view where myocardial tracking is mainly based on junction point and seem to be less sensitive 
to pixelization errors. 
XY and von Mises strain and stresses provided complementary information. Von Mises stresses 
take into account the shear component whereas the XY index does not. However, segmentation 
errors can generate large shear stresses, which encourages keeping the XY index that neglects such 
stresses. Shear strain and stresses are affected by errors, especially in regions such as left-right 
ventricular junctions in short axis. For this reason, these regions should not be included. Even with 
the use of calibrated contours, left-right ventricular junctions may result in important estimation 
errors. 
Two routes were possible to estimate myocardial strain and stresses: linear- and cumulative-based 
estimation. Linear-based estimation is the most appropriate method to approximate the resulting 
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strain and stresses for a given myocardial displacement because it does not include transitory strain 
and stresses due to non-linear displacement of the myocardium. Moreover, the linear estimation 
technique is more realistic because the hyperelasticity is taken into account as the apparent Young 
Modulus is directly estimated for the given deformation. However cumulative-based estimation of 
strain and stresses may be more appropriate for large displacements as it allows mesh 
restructuration at each phase. Strain and stresses errors due to large displacements may affect both 
linear- and cumulative-based techniques, especially during late diastole, i.e., rapid filling phases. 
One workaround is to estimate strain and stresses iteratively by dividing displacements into 
multiple steps while applying a mesh restructuration at each step.  
During the cardiac cycle, the myocardium experiences two types of deformations: an active 
contraction where myocardial fibers are stimulated to contract, and a passive relaxation where 
myocardial fibers relax. During early diastole, the myocardium is under a passive relaxation with 
a small component of active tension where ventricular pressure is constant while ventricular 
volumes increase due to blood inflow. During late diastole, the myocardium is mostly under 
passive relaxation, but with a slight increase in ventricular pressure and volumes due to auricular 
contraction. Finite-element analysis may be appropriate to the simulation of the late diastole only. 
In this case, from a mechanical point of view, ventricular pressure may be considered as loading 
conditions while myocardial deformation as resulting output [63]. We chose a different approach 
to be able to simulate both systole and diastole using myocardial displacements estimated from 
cine-CMR images as loading conditions.  
The myocardium tends to follow an anisotropic mechanical behavior. However, during an 
experimental equal biaxial loading, the elasticity modulus tends to be isotropic [73]. Moreover, 
through the thickness of the myocardial wall, the presence of multiple fiber directions has been 
reported [279]. The combination of the three main directions of fibers, i.e., circular, oblique and 
helical, further justify our hypothesis of an isotropic model. Taking into account the anisotropic or 
possibly orthotropic behavior of the myocardium using MR-based diffusion tensor imaging will 
require important time to acquire volunteers’ data, segment the images, fit the models and 
implement such data.  
Both tissue Doppler-based strain imaging and speckle tracking echocardiography has been used to 
detect anthracycline cardiotoxicity. An important decrease of myocardial radial strain was reported 
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in rats who received moderate doses of doxorubicin [35, 280]. In humans, in both adults and 
children, systolic myocardial deformation was reduced with a significant decrease in both radial, 
circumferential and longitudinal strain after low-dose anthracycline treatment [281, 186, 282-286]. 
However, none of these studies have investigated myocardial strain during diastolic relaxation. To 
the best of our knowledge, our study is the first to use cine MRI to estimate 2D myocardial strain 
during both systole and diastole. Moreover, our finding for strain during systolic contraction is 
similar to these studies. 
Three main limitations were encountered during this study. First, the technique presented in this 
paper did not take into account the through-plane motion of the myocardium [268]. In order to 
estimate the real stains and stresses that the myocardium undergoes during a specific cardiac cycle, 
advanced techniques that correct for the 3-dimensional through-plane motion [273, 287] would 
have to be used. For that reason, the presented strain and stresses should not be taken as real values 
of myocardial strain and stresses, but rather as indices used for the purpose of qualitative 
comparison between volunteers. Secondly, strain and stresses errors may be cumulated due to 
segmentation errors when using cumulative estimation techniques. However, by slightly smoothing 
the temporal displacement of myocardial contours through the cardiac cycle, these segmentation 
errors can be reduced significantly. Finally, meshing myocardial area required several steps to 
make sure the quality of the mesh was suitable for myocardial displacement. Although, phase-to-
phase displacement may keep deformations small, comparing two distant phases with large 
myocardial deformations can result in wrong strain and stresses estimation, especially if the 
meshing size is small. During mesh optimization, we tried to keep the mesh size as homogenous 
as possible within the myocardial area along with an optimal angle size (~60°), while keeping at 
least two triangles within the myocardial wall thickness. 
7.6 Conclusion 
Our new skeleton-based technique provided robust results and accurate tracking of myocardial 
tissue for further quantification of apparent strain and mechanical stresses. Cumulative-based 
estimation of strain and stresses allows mesh restructuration at each phase and thus, is more 
appropriate for large displacements. The apparent strain and stresses were significantly lower in 
doxorubicin-treated ALL survivors, which may indicate a reduction in myocardial contractile and 
relaxation function. Taking into account the non-linear myocardial displacements through this 
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cumulative-based estimation of strain and stresses help in detecting any alterations in myocardial 
tissue properties. 
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CHAPTER 8 GENERAL DISCUSSION 
The four objectives that were originally set were all met. First, we reviewed the different 
cardiotoxicities induced by doxorubicin. Second, we evaluated MRI T1 and T2 relaxation times 
sensitivity to detect myocardial damage. Third, we proposed a quantitative method for extracting 
and tracking 2D myocardial displacement using clinical cine MRI. Finally, we developed and 
proposed a finite-element model of the myocardium to evaluate mechanical properties changes 
within the myocardium. To answer to the two questions that were initially raised, myocardial tissue 
alterations appear to happen at a sub-clinical level, since the cardiac function remained normal in 
most of the cancer survivors included in this study. There cardiomyopathies affect both the 
morphology and the function part of the heart. Whether these alterations will progress toward a 
more damaging cardiomyopathies remain an open question.  
The combined use of multi-parametric MRI (T1 and T2 relaxation times), clinical indices 
(fractional shortening, wall thickening, ejection fraction and apex rotation), displacement patterns 
(displacements and deformation) and biomechanical parameters (resulting von Mises and principal 
strains and stresses) provided a better understanding of doxorubicin-induced cardiotoxicity. 
Especially as the studies were conducted using the same cohort of cancer survivors and healthy 
volunteers, the proposed techniques helped us in determining which index may have the highest 
predictive power to detect subclinical myocardial damage that is susceptible to progress toward 
clinical significance.  
The use of pre-gadolinium T1 relaxation times showed that there were local myocardial changes 
affecting some segments of the myocardium but not the whole myocardium in cancer survivors. 
The fact that HR group had higher pre-gadolinium T1 relaxation times compared to healthy 
volunteers may suggest a reduced systolic function or the presence of oedema or protein deposition 
in the myocardium. On the other hand, post-gadolinium T1 showed a significant decrease in HR 
group compared to SR group, which may also suggest that the HR group may have an abnormal 
perfusion function. This finding was further confirmed by a higher partition coefficient in HR 
group compared to HV group and also between SR group compared to HV group. Similarly, T2 
relaxation times were significantly higher in the high risk group of cancer survivors compared to 
the standard risk group. This increase may indicate alterations in the myocardial tissue at this stage.  
However, whether such changes will progress towards a clinical level or not remain to be verified. 
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The use of myocardial displacement patterns as a biomarker to predict doxorubicin-induced 
cardiotoxicity is promising, especially as myocardial contractile function seems to be affected in 
doxorubicin-treated cancer survivors. Two main limitations were encountered during this study. 
The first one being due to segmentation errors. Segmentation errors cannot be eliminated but could 
be reduced significantly by segmenting only relative displacements from one phase to another. 
Thus, instead of segmenting each phase blindly, contours should be transposed to the next phase 
and optimized relatively to the previous phase, which should result in a refined segmentation, with 
enhanced reproducibility and reduced segmentation time. Moreover, during segmentation, we had 
to take into account the signal mean within the myocardial region and use a consistent color-scale 
to efficiently segment the myocardium. Varying the color-scale could result in either a thinner or 
thicker myocardial wall, which could alter indices estimation such as thickening fraction. The 
second limitation is related to pixelation effects when extracting myocardial skeleton curves. 
Several curve smoothing steps were required since skeleton curves were calculated in pixelated 
manner. To project skeleton curves on myocardial contours, we previously used an algorithm that 
detect proximal points. This technique did not work since it required strong smoothing to avoid 
projection lines crossing each other’s. Moreover, due to myocardial wall contraction during the 
systolic stage, the algorithm resulted in errors near RV-LV junctions when trying to project 
skeletons into myocardial contours. Unfortunately, this problem persisted even when using 
perpendicular projections of the skeleton onto myocardial contours. Thus, we had to limit segments 
extremities and exclude RV-LV junctions. 
Finally, the use of strain and stress indices seems the most susceptible to detect doxorubicin-
induced cardiotoxicity. Reduction in strains and stresses during the cardiac cycle (see Appendix B) 
was see in doxorubicin-treated cancer survivors which may indicate a reduction in myocardial 
contractile function. Though, three main limitations were encountered during strains and stresses 
estimation. The first one reside in the segmentation process and whether to include or not papillary 
muscles and others structure. This limitation remains an important factor that may have a 
significant effect on the results. The second limitation is related to the choice of constitutive law. 
The proposed model consists of an isotropic hyperplastic model of myocardial mechanical 
behavior. While a better model would take into account the anisotropic behavior of the 
myocardium. This limitation should persist unless myocardial fibers orientation is known. We 
believe that the use of simulated fibers orientation should considerably enhance the finite-element 
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model. Finally, the last limitation is related to the through-plane motion, which was not taken into 
account. Because of such omission, the resulting strains and stresses should not be used for 
quantitative purposes. The use of a 3D model may be required to take into account such third-
dimensional motion. 
To answer to the two questions raised earlier, we can say that several cardiomyopathies are induced 
by doxorubicin. These cardiomyopathies affect not only the myocardial contractile function, but 
also the tissue composition of the myocardium. The fact that cancer survivors, especially the HR 
group, had slightly higher pre-gadolinium T1 relaxation times compared to healthy volunteers may 
suggest reduced systolic function or the presence of oedema or protein deposition. Furthermore, 
the partition coefficient which is insensitive to post-enhancement duration was significantly 
elevated in cancer survivors (both SR and HR group) compared to HV group, which may suggest 
the presence of a reduced perfusion function. The higher T2 values in HR group compared to SR 
group suggest that the fat and water contents of the myocardium may altered in this group of cancer 
survivors. On the other hand, the fact that myocardial displacement patterns along with left-
ventricular apex rotation were significantly lower in cancer survivors compared to healthy 
volunteers suggest that the myocardial contractile function is definitely reduced in our cohort of 
cancer survivors. Similarly, the apparent strains and stresses were also significantly lower in cancer 
survivors compared to healthy volunteers, which should further confirm the presence of a reduced 
myocardial contractile function.  
The second question which asks whether these doxorubicin-induced cardiomyopathies alter the 
myocardial function or not, we can say that most of alterations that affect the cardiac function 
remained subclinical. Thickening fraction remained similar between cancer survivors and healthy 
volunteers in all planes. Left ventricular ejection fraction was significantly reduced in cancer 
survivors compared to healthy volunteers when estimating it using 2-chamber or 4-chamber view. 
However, when using conventional short-axis view, the index failed to detect any significant 
differences between both SR and HR groups or between cancer survivors and healthy volunteers. 
On the other hand, diastolic fraction in 4-chamber view was lower in cancer survivors as compared 
to healthy volunteer, but only for the right ventricle. Left ventricular diastolic fraction in 4-chamber 
view was similar between cancer survivors and healthy volunteers. Similarly, LV diastolic fraction 
was similar between cancer survivors and healthy volunteers in 2-chamber and short-axis views. 
Conversely, cancer survivors had significant lower rotation angles compared to healthy volunteers. 
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Furthermore, SR group had slightly lower rotation angle than HR group, which may again suggest 
that the contractile function of the myocardium may be altered. 
One common limitation to our study is related to the fact that our cohort of cancer survivors and 
healthy volunteers was relatively small. To further confirm the clinical application of our results, 
a study with a larger cohort of cancer survivors and healthy volunteers will be required, especially 
as the cohort of cancer survivors was further divided into SR and HR group. Another limitation to 
our models is related to the time required to segment patients’ images. In this study, we choose the 
semi-automatic segmentation, which requires considerable time to segments patients’ images. The 
reason behind this choice is because semi-automatic segmentation is often more accurate compared 
to automatic segmentation. Also, in order to segment a short-axis slice, which include 25 images, 
the required time is approximately 20 to 30 minutes, which is significant. However, we proposed 
an interpolation-based segmentation, which should reduce segmentation time significantly. To 
segment one slice of 25 images, segmentation time may be reduced to up to 2 minutes by including 
contours interpolation during the segmentation process. Finally, the last limitation is related to the 
choice of our cohort of cancer survivors and the cumulative doxorubicin doses received during the 
treatment. Most of cancer survivors received moderate doxorubicin-doses. Furthermore, most of 
cancer survivors have also received dexrazoxane as a cardioprotective agent, which may have 
inhibited doxorubicin-related cardiotoxicity. 
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CHAPTER 9 CONCLUSION AND RECOMMENDATIONS 
To conclude, the presented techniques for detecting doxorubicin-induced cardiotoxicity are all 
promising. Most of myocardial injuries reported in this doctoral project remained at a subclinical 
level. Whether these changes will progress toward a more damaging cardiac injury such as late 
congestive heart failure remain an open question. We believe that all of the presented indices may 
have a say in detecting doxorubicin-induced cardiotoxicity.  
This work is presented as a preliminary model for the detection of doxorubicin-induced 
cardiotoxicity. However, several improvements can be made to the presented techniques. The first 
improvement resides in the segmentation process. Segmentation process is considered the main 
source of errors when tracking myocardial displacements. Moreover, semi-automated 
segmentation is time consuming and may in this case not allow clinical application. Segmenting 
one slice takes between 30 to 60 seconds while segmenting the whole cardiac cycle, i.e., 30 slices, 
may take up to 30 minutes, depending on the user’s ability to segment myocardial contours. 
However, with the use of slice interpolation (see Appendix A) one may reduce segmentation time 
to up to 2 minutes for the whole cardiac cycle. Moreover, with the use of smoothing and elastic 
registration (Appendix B and C), one may further reduce segmentation times. This reduction in 
time is important because segmenting of multiple heart may take considerable time. 
The second improvement resides in the fine-element model (Appendix D).  Currently, mechanical 
strains and stresses are obtained from myocardial displacements used as loading conditions 
(Appendix E and F). A hyperelastic model with an isotropic distribution of Young’s Modulus was 
used. However, the heart follows an anisotropic behaviour. In this case, an improved model would 
include an orthotropic or possibly an anisotropic Young’s Modulus in order to estimate strains and 
stresses. 
The last improvement will be considering a more complex 3D model of the heart (Appendix G). 
Such model would take into account the through-plane motion and will benefit strains and stresses 
estimation. Currently 2D strains and stress are proposed only as a preliminary model because the 
through-plane motion was omitted. However, in order to estimate the actual strains and stresses 
that the myocardium undergoes during a specific interval of the cardiac cycle, one would have to 
include the through-plane motion. Finally, we propose a segmentation software developed under 
MatLab interface. This software facilitates the whole segmentation process by allowing semi-
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automated segmentation (Appendix H). The use of template is proposed to reduce segmentation 
times. Manually segmenting a slice which includes 30 images would take approximately 30 
minutes. However, by the use of templates and Bezier curves, we could reduce such segmentation 
to approximately 5 minutes. 
This work should serve as building stage for a more complex 3D model of the human heart. A 
compromise however needs to be made between processing time and complexity of the model. We 
believe that with the use of a more complex 3D model, many of the previously discussed limitation 
should be solved in an easier manner. The inclusion of the through-plane motion would enhance 
significantly out estimation of myocardial displacements along with indices such as mechanical 
strains and stresses. 
Finally, for the medium and long term, this project contributes to the advancement of knowledge 
in the field of doxorubicin-induced cardiomyopathies, myocardial tracking and multiparametric 
analysis of the myocardium. A graphical interface was designed in close collaboration with 
cardiologists, for myocardial segmentation, 3D visualization of myocardial contours and automatic 
processing of myocardial contours to extract T1 and T2 relaxation times, myocardial displacements 
patters and myocardial mechanical strains and stresses. The integration of this software tool at the 
clinical level is a first concrete step towards a more comprehensive management of doxorubicin-
induced cardiomyopathies. 
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APPENDIX A – MYOCARDIAL CYCLE SIMULATION FROM KEY 
PHASES 
Using all phases to simulate myocardial contraction provide reference contour data, on the other 
hand may consume an important amount of work in order to segment the myocardium through the 
whole cardiac cycle (i.e., ~25-30 phases). The use of templates and «contours initialisation 
technique» facilitated greatly this work. However, in order to speed up segmentation process, one 
may either combine manual segmentation with elastic registration or if permissible, segment only 
key phases of the cardiac cycle and interpolate the temporal displacements of myocardial contours. 
In both cases, a manual post-correction of contours is required to obtain accurate contours. The 
first phase, i.e., end-diastole, is most of the time required along with the end-systolic and end-early-
diastole (i.e., the first phase representing late diastole period). These three phases provide key 
geometries of the myocardium during the cardiac cycle (Figure A.1), and in any case, should be 
manually segmented. To improve accuracy, a compromise can be made between manual post-
correction of contours, and adding more phases to the initial segmentation process to interpolate 
myocardial displacement. Segmenting 30 phases, using templates and «contours initialisation 
technique» may require between one to two minutes of work. With the combination of 
interpolation/correction or elastic-registration/correction (Figure A.2), segmentation time may be 
reduced significantly. 
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Figure A.1: Temporal interpolation of myocardial contours using: 3 key phases + 7x1-phase 
elastically registered steps (top) and 3 key phases + 7x2-phase elastically registered steps (bottom). 
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Figure A.2: Temporal interpolation of myocardial contours using: 3 key phases + 7x1-phase 
elastically registered steps (top) and 3 key phases + 7x2-phase elastically registered steps (bottom). 
 
An attempt to reduce myocardial displacements was done by interpolating a slice between each 
two phases of the cardiac cycle (Figure A.3). Which resulted in 51 images: 26 (initial) plus 25 
(interpolated) images. However, even with smaller myocardial displacements between two phases 
did not improve myocardial tracking accuracy. 
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Figure A.3: Temporal interpolation of myocardial contours using elastic registration with: 26 
phases (top) and 26+25=51 reconstructed images with interpolated mid-phases (bottom). Resulting 
contours are shown during the 5th phase, i.e., mid-systole. 
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APPENDIX B – MYOCARDIAL DISPLACEMENTS SMOOTHING 
In order to reduce segmentation errors, while trying to avoid contours displacements, a slight 
smoothing was added to the x and y components of the temporal displacement of each point along 
myocardial contours. By doing so, contours displacements were fairly stabilized through the 
cardiac cycle, while keeping as much as possible the accuracy of the contours (see Figures B.1 to 
B.3). Moreover, smoothing may significantly reduce segmentation fluctuations, i.e., segmentation 
errors, during low displacement periods. Smoothing was accomplished using a 1D custom smooth 
function with an iterative correction where the resulting points are obtained as follow (for a single 
iteration): 
 
𝑃𝑖𝑓𝑖𝑛𝑎𝑙 =
𝑃𝑖−1𝑖𝑛𝑖𝑡𝑖𝑎𝑙
6
+
2 ∗ 𝑃𝑖𝑖𝑛𝑖𝑡𝑖𝑎𝑙
3
+
𝑃𝑖+1𝑖𝑛𝑖𝑡𝑖𝑎𝑙
6
              𝑖 = 2…𝑒𝑛𝑑 − 1    (𝐵1) 
 
Points were smoothed iteratively using a smoothing degree, i.e., number of iteration, which was 
set to 3 during our simulation. The weights have been set to: [
1
6
2
3
1
6
], however, for a stronger 
correction, one may apply a stronger correction by setting a higher weight to adjacent points, i.e., 
[
1
4
1
2
1
4
]. Results were also compared to the Matlab function “smooth.m” from the Matlab 
Central’s File Exchange [288].  
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Figure B.1: End-diastolic contours with temporal smoothing in short-axis view. 
 
 
Figure B.2: End-systolic contours with temporal smoothing in short-axis view. 
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Figure B.3: Early-diastole contours with temporal smoothing in short-axis view. 
 
Both smoothing functions fairly preserve myocardial geometry, however with Custom smoothing 
function, one may add one or several points as fixed points, where no smoothing is applied. In our 
context, the first and last points, representing the end-diastole/systole-start were fixed as reference 
points (See Figure B.4). This was necessary because a simple smoothing function may significantly 
alter these points, which may result in significant geometric variation, if no boundary limit is 
applied. 
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Figure B.4: Example of an X- and Y-component smoothing for a point taken along the endocardial 
RV curve. 
 
The zigzag course seen from myocardial displacement paths (Figure B.5), caused mainly by 
segmentation errors, was considerably reduced after smoothing myocardial displacements. 
However, the torsional aspect of the curves, was kept fairly similar (see Figure B.5). 
 
Figure B.5: Displacement paths in short-axis view: Unsmoothed (a), smoothed using “Smooth.m” 
(b) and smoothed using Custom smoothing (c). 
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APPENDIX C – MYOCARDIAL DISPLACEMENTS ESTIMATION USING 
ELASTIC REGISTRATION 
Elastic registration [239] failed to provide a robust estimation for myocardial displacements using 
clinical cine MRI. Particularly when estimating displacements from two distant phases of the 
cardiac cycle. Using different levels of image pixels’ depth (see Figure C.1) had little to no effects 
on the final result (Figure C.2). The only difference was that unsigned integer 16 (uint16) kept most 
of the signal unchanged while unsigned integer 8 (uint8) resulting in an image with reduced 
sharpness and details due to depth conversion, i.e., reduction. 
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Figure C.1: Myocardial displacement field in short-axis view using: contour tracking as a reference 
(a), compared with elastic registration with: uint8 images/no contrast enhancement (b), uint8 
images/with contrast enhancement (c), uint16 images/no contrast enhancement (d) and uint16 
images/no contrast enhancement (e). 
 
 
Figure C.2: Myocardial strains distribution in short-axis view from: contour tracking as a reference 
(a), compared with elastic registration with: uint8 images/no contrast enhancement (b), uint8 
images/with contrast enhancement (c), uint16 images/no contrast enhancement (d) and uint16 
images/no contrast enhancement (e). 
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Windowing myocardial region of interest, i.e., zooming, or enhancing images resolution (Figure 
C.3) had little effect on myocardial tracking accuracy using elastic registration technique (Figure 
C.4). 
 
Figure C.3: Myocardial displacement field in short-axis view using: unzoomed 256x256 images 
(a), compared with: zoomed 256x256 images (b), unzoomed 512x512 images (c) and zoomed 
512x512 images (d). 
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Figure C.4: Myocardial strains distribution in short-axis view from: unzoomed 256x256 images 
(a), compared with: zoomed 256x256 images (b), unzoomed 512x512 images (c) and zoomed 
512x512 images (d). 
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APPENDIX D – FINITE-ELEMENT ANALYSIS DIAGRAM 
 
Figure D.1: Myocardial finite element analysis methodology. 
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APPENDIX E – FINITE-ELEMENT EQUATIONS 
The 3D equations [289] of equilibrium (derived from summation of forces in 𝑥, 𝑦 and 𝑧 directions) 
over an infinitesimal element are: 
 
𝜕𝜎𝑥
𝜕𝑥
+
𝜕𝜏𝑥𝑦
𝜕𝑦
+
𝜕𝜏𝑥𝑧
𝜕𝑧
+ 𝑓𝑥 = 0       (E1) 
𝜕𝜏𝑥𝑦
𝜕𝑥
+
𝜕𝜎𝑦
𝜕𝑦
+
𝜕𝜏𝑦𝑧
𝜕𝑧
+ 𝑓𝑦 = 0       (E2) 
𝜕𝜏𝑥𝑧
𝜕𝑥
+
𝜕𝜏𝑦𝑧
𝜕𝑦
+
𝜕𝜎𝑧
𝜕𝑧
+ 𝑓𝑧 = 0       (E3) 
 
For an isotropic material, the constitutive equation which state the relationship between stress and 
strains (relative displacements) is: 
 
{𝜎} = [𝐷]{𝜀}        (E4) 
 
Where, 
 
{𝜎} = {𝜎𝑥 𝜎𝑦 𝜎𝑦 𝜏𝑥𝑦 𝜏𝑦𝑧 𝜏𝑥𝑧}𝑇      (E5) 
{𝜖} = {𝜖𝑥 𝜖𝑦 𝜖𝑧 𝛾𝑥𝑦 𝛾𝑦𝑧 𝛾𝑥𝑧}𝑇      (E6) 
And, 
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[𝐷] =
𝐸
(1+𝜐)(1−2𝜐)
[
 
 
 
 
 
 
 
 
 
 
 
1 − 𝜐 𝜐 𝜐 0 0 0
𝜐 1 − 𝜐 𝜐 0 0 0
𝜐 𝜐 1 − 𝜐 0 0 0
0 0 0
1−2𝜐
2
0 0
0 0 0 0
1−2𝜐
2
0
0 0 0 0 0
1−2𝜐
2 ]
 
 
 
 
 
 
 
 
 
 
 
    (E7) 
 
However, for an anisotropic material [290] the 𝐷 matrix is: 
 
[𝐷] =
[
 
 
 
 
 
 
 
 
 
 
𝐷11 𝐷12 𝐷13 𝐷14 𝐷15 𝐷16
𝐷21 𝐷22 𝐷23 𝐷24 𝐷25 𝐷26
𝐷31 𝐷32 𝐷33 𝐷34 𝐷35 𝐷36
𝐷41 𝐷42 𝐷43 𝐷44 𝐷45 𝐷46
𝐷51 𝐷52 𝐷53 𝐷54 𝐷55 𝐷56
𝐷61 𝐷62 𝐷63 𝐷64 𝐷65 𝐷66]
 
 
 
 
 
 
 
 
 
 
            (E8) 
 
Where 𝐷𝑖𝑗 = 𝐷𝑗𝑖, which lead the problem to 21 unknown material parameters. For materials that 
have two or three planes of material symmetry (orthotropic) such as muscle fibers (with two planes 
of symmetry) aligned with 𝑥 axis, the number of unknowns is reduced to 9 and the relation become: 
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{
 
 
 
 
𝜖𝑥
𝜖𝑦
𝜖𝑧
𝛾𝑥𝑦
𝛾𝑦𝑧
𝛾𝑥𝑧}
 
 
 
 
=
[
 
 
 
 
 
 
 
 
 
 
 
1
𝐸𝑥
−
𝜐𝑥𝑦
𝐸𝑦
−
𝜐𝑥𝑧
𝐸𝑧
0 0 0
−
𝜐𝑦𝑥
𝐸𝑥
1
𝐸𝑦
−
𝜐𝑦𝑧
𝐸𝑧
0 0 0
−
𝜐𝑧𝑥
𝐸𝑥
−
𝜐𝑧𝑦
𝐸𝑦
1
𝐸𝑧
0 0 0
0 0 0
1
𝐺𝑥𝑦
0 0
0 0 0 0
1
𝐺𝑦𝑧
0
0 0 0 0 0
1
𝐺𝑧𝑥]
 
 
 
 
 
 
 
 
 
 
 
{
 
 
 
 
𝜎𝑥
𝜎𝑦
𝜎𝑧
𝜏𝑥𝑦
𝜏𝑦𝑧
𝜏𝑥𝑧}
 
 
 
 
= [𝐷]−1{𝜎} (E9) 
 
Where 𝐸𝑥 and 𝐸𝑦 = 𝐸𝑧 are elastic moduli along 𝑥, 𝑦 and 𝑧 directions,  𝜐𝑦𝑧 ≈   𝜐𝑥𝑦 = 𝜐𝑥𝑧 are 
Poisson ratios and 𝐺𝑦𝑧 , 𝐺𝑥𝑦 = 𝐺𝑥𝑧 are shear moduli, reducing the number of unknowns to 6: two 
directional moduli, two Poisson ratios and two shear moduli. In order to avoid system singularities, 
The Poisson’s ratio is set at 𝜐 = 0.45 − 0.49. Although the myocardium is not completely 
incompressible, it is reported that myocardial volume change during the cardiac cycle is no more 
than 4%, and less than 2% in any direction [243]. 
The kinematic equation which derive strains from displacement (for small displacements) is: 
 
{
 
 
 
 
𝜖𝑥
𝜖𝑦
𝜖𝑧
𝛾𝑥𝑦
𝛾𝑦𝑧
𝛾𝑥𝑧}
 
 
 
 
=
{
 
 
 
 
 
 
 
 
𝜕𝑢
𝜕𝑥
𝜕𝑣
𝜕𝑦
𝜕𝑤
𝜕𝑧
𝜕𝑣
𝜕𝑥
+
𝜕𝑢
𝜕𝑦
𝜕𝑤
𝜕𝑦
+
𝜕𝑣
𝜕𝑧
𝜕𝑤
𝜕𝑥
+
𝜕𝑢
𝜕𝑧}
 
 
 
 
 
 
 
 
      (E10) 
 
Where 𝑢, 𝑣 and 𝑤 are displacement in the 𝑥, 𝑦 and 𝑧 directions, respectively. After applying the 
weighted residual method to Equations (E1), (E2) and (E3) and writing them together, the system 
become: 
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∫
{
 
 
 
 𝜔1(
𝜕𝜎𝑥
𝜕𝑥
+
𝜕𝜏𝑥𝑦
𝜕𝑦
+
𝜕𝜏𝑥𝑧
𝜕𝑧
)
𝜔2(
𝜕𝜏𝑥𝑦
𝜕𝑥
+
𝜕𝜎𝑦
𝜕𝑦
+
𝜕𝜏𝑦𝑧
𝜕𝑧
)
𝜔3(
𝜕𝜏𝑥𝑧
𝜕𝑥
+
𝜕𝜏𝑦𝑧
𝜕𝑦
+
𝜕𝜎𝑧
𝜕𝑧
)}
 
 
 
 
Ω
𝑑Ω + ∫ {
𝜔1𝑓𝑥)
𝜔2𝑓𝑦
𝜔3𝑓𝑧
}
Ω
− ∫ {
𝜔1𝜙𝑥
𝜔2𝜙𝑦
𝜔3𝜙𝑧
}𝑑𝛬 = 0
𝛬
   (E11) 
 
Where 𝛬 is the imposed boundary condition that can be either a displacement or traction defined 
over a sub-region 𝛬 ∈  Ω. Applying integration by parts and substituting the constitutive equation 
and the kinematic equation in the first part of Eq. (E11) gives: 
 
∫ [𝐵]𝑇[𝐷][𝐵]
Ω𝑒
𝑑Ω{𝑑} − ∫ [𝑁]𝑇 {
𝑓𝑥
𝑓𝑦
𝑓𝑧
}𝑑𝛬 + ∫
{
 
 
 
 
 
 
 
 
𝑠𝑛−𝑠
𝑠𝑛−𝑠𝑚
0 0
0
𝑠𝑛−𝑠
𝑠𝑛−𝑠𝑚
0
0 0
𝑠𝑛−𝑠
𝑠𝑛−𝑠𝑚
𝑠−𝑠𝑚
𝑠𝑛−𝑠𝑚
0 0
0
𝑠−𝑠𝑚
𝑠𝑛−𝑠𝑚
0
0 0
𝑠−𝑠𝑚
𝑠𝑛−𝑠𝑚}
 
 
 
 
 
 
 
 
{
𝜙𝑥
𝜙𝑦
𝜙𝑧
}
𝑠𝑛
𝑠𝑚
= 0
Ω𝑒
  (E12) 
 
Where the element stiffness matrix, integrated over element domain Ω𝑒, is 
 
[𝐾𝑒] = ∫ [𝐵]𝑇[𝐷][𝐵]
Ω𝑒
𝑑Ω      (E13) 
 
As our model uses 3-node triangles or 4-node tetrahedron, the linear shape function for each 
element is 
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{
𝑢
𝑣
𝑤
} = [
𝐻1 0 0 𝐻2 0 0 𝐻3 0 0 𝐻4 0 0
0 𝐻1 0 0 𝐻2 0 0 𝐻3 0 0 𝐻4 0
0 0 𝐻1 0 0 𝐻2 0 0 𝐻3 0 0 𝐻4
]
{
 
 
 
 
 
 
 
 
 
 
𝑢1
𝑣1
𝑤1
𝑢2
𝑣2
𝑤2
𝑢3
𝑣3
𝑤3
𝑢4
𝑣4
𝑤4}
 
 
 
 
 
 
 
 
 
 
= [𝑁]{𝑑}  
 (E14) 
 
Where {𝑑} is the nodal displacement vector. Substituting Eq. (E14) into the kinematic equation 
results in 
 
{
 
 
 
 
𝜖𝑥
𝜖𝑦
𝜖𝑧
𝛾𝑥𝑦
𝛾𝑦𝑧
𝛾𝑥𝑧}
 
 
 
 
=
[
 
 
 
 
 
 
 
 
 
𝜕𝐻1
𝜕𝑥
0 0
𝜕𝐻2
𝜕𝑥
0 0
𝜕𝐻3
𝜕𝑥
0 0
𝜕𝐻4
𝜕𝑥
0 0
0
𝜕𝐻1
𝜕𝑦
0 0
𝜕𝐻2
𝜕𝑦
0 0
𝜕𝐻3
𝜕𝑦
0 0
𝜕𝐻4
𝜕𝑦
0
0 0
𝜕𝐻1
𝜕𝑧
0 0
𝜕𝐻2
𝜕𝑧
0 0
𝜕𝐻3
𝜕𝑧
0 0
𝜕𝐻4
𝜕𝑧
𝜕𝐻1
𝜕𝑦
𝜕𝐻1
𝜕𝑥
0
𝜕𝐻2
𝜕𝑦
𝜕𝐻2
𝜕𝑥
0
𝜕𝐻3
𝜕𝑦
𝜕𝐻3
𝜕𝑥
0
𝜕𝐻4
𝜕𝑦
𝜕𝐻4
𝜕𝑥
0
0
𝜕𝐻1
𝜕𝑧
𝜕𝐻1
𝜕𝑦
0
𝜕𝐻2
𝜕𝑧
𝜕𝐻2
𝜕𝑦
0
𝜕𝐻3
𝜕𝑧
𝜕𝐻3
𝜕𝑦
0
𝜕𝐻4
𝜕𝑧
𝑑𝐻4
𝑑𝑦
𝑑𝐻1
𝑑𝑧
0
𝜕𝐻1
𝜕𝑥
𝜕𝐻2
𝜕𝑧
0
𝜕𝐻2
𝜕𝑥
𝜕𝐻3
𝜕𝑧
0
𝜕𝐻3
𝜕𝑥
𝜕𝐻4
𝜕𝑧
0
𝑑𝐻4
𝑑𝑥 ]
 
 
 
 
 
 
 
 
 
{
 
 
 
 
 
 
 
 
 
 
𝑢1
𝑣1
𝑤1
𝑢2
𝑣2
𝑤2
𝑢3
𝑣3
𝑤3
𝑢4
𝑣4
𝑤4}
 
 
 
 
 
 
 
 
 
 
= [𝐵]{𝑑} 
(E15) 
 
Finally, replacing matrix [𝐷] from Eq. (E4), for a specific material (isotropic or orthotropic), and 
matrix [𝐵] from Eq. (E15), for a tetrahedron element (or 2D or 3D elements), into Eq. (E13) results 
in element stiffness matrix 
 
[𝐾𝑒] = [𝐵]𝑇[𝐷][𝐵]𝑉       (E16) 
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Where 𝑉 represents the tetrahedron volume or triangular area in 2D. 
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APPENDIX F – STRAINS AND STRESSES DISTRIBUTIONS FOR EACH 
CARDIAC INTERVAL USING VON MISES AND XY INDICES: 
CUMULATIVE VS. LINEAR TECHNIQUE 
Linear and cumulative strains and stresses are shown using either von Mises or XY index (Figures 
F.1 to F.5). Results are compared between SR and HR group and between cancer survivors and 
healthy volunteers. 
 
Figure F.1: “Linear” von Mises strains and stresses. 
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Figure F.2: “Linear” XY strains and stresses. 
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Figure F.3: “Cumulative” von Mises strains and stresses. 
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Figure F.4: “Cumulative” XY strains and stresses. 
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Linear and cumulative estimation techniques for strains and stresses are compared in Table F.1 
Table F.1: linear vs. cumulative estimation techniques for strains and stresses 
Technique 
Displacements 
from: 
Advantages Limits 
Linear 
Raw contours 
• Accurate tracking 
• Cancel residual 
strains/stresses 
• Sliding 
phenomenon if 
large deformations 
Elastic 
registration 
• Uniform displacement 
flow 
• Poor tracking if 
large deformations 
Calibrated 
contours 
• Excellent accuracy • Pixelation effects 
Cumulative 
Raw contours 
• Mesh stabilisation every 
phase 
• Keep residual 
strains/stresses 
Elastic 
registration 
• Acceptable accuracy 
• Mesh stabilisation every 
phase 
• Keep residual 
strains/stresses 
Calibrated 
contours 
• Excellent accuracy • Pixelation effects 
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APPENDIX G – 3D MODELING OF THE HEART: PERSPECTIVES 
2-dimensional modeling of the myocardium in 2-chamber, 4-chamber and short-axis views serves 
as a building block for a 3D model. Current imaging techniques rely mainly on 2D images such as 
2D cine MRI. The combination of these 3 orientations may provide enough information to estimate 
3D myocardial displacement at any point. In this work, we concentrated our efforts mainly in 2D 
myocardial tracking in order to develop an accurate estimation technique of myocardial 
displacement. At this point, from cine MRI images, one promising technique is to reconstitute 
contours from the myocardial skeleton by projection myocardial skeleton curves back into 
myocardial contours, as discussed previously.  The calibration of myocardial contours is mainly 
done using key skeleton-based points (Fig G.1), which can be considered as anatomical references 
from tracking. Using these resulting contours, i.e., calibrated contours, one could estimate intra-
myocardial displacement at any given point using an interpolator function such as kriging. 
Furthermore, such points may provide a stable parametrization for 3D contours (Fig G.2), which 
paves the way for 3D myocardial tracking (Figure G.3). 
 
 
Figure G.1: Key skeleton-based anatomical points which may be used for 3D myocardial tracking. 
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Figure G.2: Preliminary model of the ventricular myocardium obtained using 3-planes 
segmentation. A, 4-chambers view (long vertical axis). B, 2-chambers view (long horizontal axis). 
 
 
Figure G.3: Preliminary model of the ventricular myocardium obtained using 3-planes 
segmentation. 
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APPENDIX H – CARDIOLAB: A NEW SEGMENTATION SOFTWARE 
The main segmentation software used to segment cine MRI images and display 3D segmentation 
is shown in Figure H.1: 
 
Figure H.1: The main segmentation software which uses template based on Bezier curves. 
 
 
 
